Crystalline forms of TYK2 inhibitors

Abstract

The present invention relates to a compound of formula (I): [Formula 1] JPEG2023521631000051.jpg9890 A crystalline form of a compound having the formula:

Description

[Technical field]

[0001] The present invention relates to crystalline forms of the compound 2-(2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)anilino]oxazole-4-carboxamide, pharmaceutical compositions containing them, and their use in the treatment of various diseases, such as autoimmune diseases. [Background technology]

[0002] Protein kinases constitute a large family of structurally related enzymes responsible for controlling a wide variety of signal transduction processes within cells (Hardie and Hanks (1995) The Protein Kinase Facts Book. I and II, Academic Press, San Diego, CA). Kinases can be classified into families according to the substrates they phosphorylate (e.g., protein-tyrosine, protein-serine / threonine, lipids, etc.). Broadly corresponding sequence motifs have been identified for each of these kinase families (e.g., Hanks and Hunter, FASEB J., (1995) 9.576-596; Knighton, et al., Science, (1991) 253, 407-414; Hiles, et al., Cell, (1992) 70, 419-429; Kunz, et al., Cell, (1993) 73, 585-596; Garcia-Bustos, et al., EMBO J., (1994) 13, 2352-2361).

[0003] Protein kinases can be characterized by their mechanisms of regulation. These mechanisms include, for example, autophosphorylation, transphosphorylation by other kinases, protein-protein interactions, protein-lipid interactions, and protein-polynucleotide interactions. An individual protein kinase can be regulated by more than one mechanism.

[0004] Kinases regulate many different cellular processes, including but not limited to proliferation, differentiation, apoptosis, motility, transcription, translation and other signaling processes, by adding phosphate groups to target proteins. These phosphorylation events act as molecular on / off switches that can modulate or regulate the biological function of the target protein. Phosphorylation of target proteins occurs in response to a variety of extracellular signals (such as hormones, neurotransmitters, growth and differentiation factors), cell cycle events, environmental or nutritional stresses, and the like. Suitable protein kinases function in signaling pathways to activate or inactivate (directly or indirectly), for example, metabolic enzymes, regulatory proteins, receptors, cytoskeletal proteins, ion channels or pumps, or transcription factors. Uncontrolled signaling through dysregulated protein phosphorylation has been implicated in many diseases, including, for example, inflammation, cancer, allergies / asthma, immune system diseases and conditions, central nervous system diseases and conditions, and angiogenesis.

[0005] The Janus kinase (JAK) family is a family of intracellular non-receptor tyrosine kinases ranging in size from 120 to 140 kDa that transmit cytokine-mediated signals via the JAK-STAT pathway. The JAK family plays a role in the cytokine-dependent regulation of proliferation and function of cells involved in the immune response. Currently, four mammalian JAK family members are known: JAK1, JAK2, JAK3, and TYK2. JAK1, JAK2, and TYK2 are ubiquitously expressed, whereas JAK3 is expressed in myeloid and lymphoid lineages. JAK family members are non-receptor tyrosine kinases that associate with many hemotopoietin cytokines, receptor tyrosine kinases, and GPCR kinases.

[0006] Each JAK kinase protein has a kinase domain and a catalytically inactive pseudokinase domain. JAK proteins bind to cytokine receptors via their amino-terminal FERM (band 4.1, ezrin, radixin, moesin) domains. After cytokines bind to their receptors, JAKs are activated and phosphorylate the receptors, thereby creating docking sites for signaling molecules, particularly members of the signal transducer and activator of transcription (STAT) family (Yamaoka et al, 2004. The Janus kinases (Jaks). Genome Biology 5(12):253).

[0007] In mammals, JAK1, JAK2 and TYK2 are ubiquitously expressed. TYK2 activates signal transducer and activator of transcription (STAT)-dependent gene expression and functional responses of interleukin 12, interleukin 23 and type I and type III interferon receptors (Papp et al., The New England Journal of Medicine, 12 September 2018, DOI:10.1056 / NEJMoa1806382 and references cited therein). These cytokine pathways have been reported to be involved in pathological processes associated with immune-mediated disorders, including psoriasis, and are distinct from responses driven by Janus kinase (JAK) 1 (JAK1), a combination of JAK1 and JAK3, JAK2, or other signaling kinases (Papp et al., supra).

[0008] Interleukin 23 (IL-23), composed of two subunits, p19 and p40, is believed to be essential for the survival and expansion of Th17 cells, which produce proinflammatory cytokines such as IL-17A, IL-17F, IL-6, and TNFα (see WO 2014 / 07466 and references cited therein). These cytokines have been reported to be important in mediating the pathobiology of many autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, and lupus.

[0009] IL-23 acts through a heterodimeric receptor consisting of IL-12Rβ1 and IL-23R.

[0010] IL-12 contains the p35 subunit in addition to the p40 subunit shared with IL-23, and acts through a heterodimeric receptor consisting of IL-12R1β and IL-12Rβ2. IL-12 is essential for the development of Th1 cells and the secretion of IFNγ, a cytokine that plays a key role in immunity by stimulating MHC expression, B cell class switching to the IgG subclass, and macrophage activation (Gracie, JA et al., ``Interleukin-12 induces interferon-gamma-dependent switching of IgG alloantibody subclass'', Eur. J. Immunol, 26:1217-1221 (1996); Schroder, K. et al., ``Interferon-gamma: an overview of signals, mechanisms and functions'', J. Leukoc. Biol, 75(2):163-189 (2004)).

[0011] TYK2 associates with the IL-12Rβ1 subunit in the IL-12 and IL-23 receptors.

[0012] The importance of p40-containing cytokines in autoimmunity is demonstrated by the findings that mice deficient in either p40, p19 or IL-23R are protected from disease in models of multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, lupus and psoriasis, among others (Kyttaris, V. C. et al., "Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL / 6-lpr / lpr mice", J. Immunol, 184:4605-4609 (2010); Hong, K. et al., "IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis like skin disorder", J. Immunol, 162:7480-7491 (1999); Hue, S. et al., "Interleukin-23 drives innate and T cell-mediated intestinal inflammation'',J.Exp.Med.,203:2473-2483(2006);Cua,DJet al.,''Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain'',Nature,421:744-748(2003);Murphy,CAet al.,''Divergent pro-and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation'', J. Exp. Med, 198:1951-1957 (2003)).

[0013] The role of TYK2 in biological responses to cytokines has been characterized using mutant human cell lines that are resistant to the action of type I interferons (IFNs) and by demonstrating that IFNα responsiveness can be restored by genetic complementation of TYK2 (Velazquez et al, 1992. Cell 70, 313-322). Further in vitro studies have implicated TYK2 in the signaling pathways of several other cytokines involved in both innate and adaptive immunity. However, TYK2 - / - Analysis of the mice revealed less severe immunological defects than expected (Karaghiosoff et al, 2000. Immunity 13, 549-560; Shimoda et al, 2000. Immunity 13, 561-671). Surprisingly, TYK2-deficient mice simply exhibited reduced responsiveness to IFNα / β, but signaled normally to interleukin 6 (IL-6) and interleukin 10 (IL-10), both of which activate TYK2 in vitro. In contrast, TYK2 is essential for IL-12 signaling, and its absence led to impaired activation of STAT4 and failure of T cells from these mice to differentiate into IFNγ-producing Th1 cells. Consistent with the involvement of TYK2 in mediating the biological effects of type I IFN and IL-12, TYK2 - / - The mice were more susceptible to viral and bacterial infections.

[0014] The first patient with autosomal recessive TYK2 deficiency was described by Minegishi et al, 2006. Immunity 25, 745-755. A homozygous deletion of four base pairs in the patient's coding DNA (GCTT at nucleotide 550 of the TYK2 gene) and the resulting frameshift mutation introduced a premature stop codon, resulting in a truncation of the TYK2 protein by 90 amino acids. The phenotype of this null mutation in human cells was much more severe than predicted by studies in mouse cells lacking TYK2. The patient presented with clinical features reminiscent of primary immunodeficiency hyper-IgE syndrome (HIES), including recurrent skin abscesses, atopic dermatitis, very high serum IgE levels, and susceptibility to multiple opportunistic infections.

[0015] TYK2 - / - Contrary to reports in mice, we found that signaling by a wide variety of cytokines was impaired, thus highlighting the non-redundant role of human TYK2 in the function of type I IFN, IL-6, IL-10, IL-12 and IL-23. An imbalance in T helper cell differentiation was also observed, with the patient's T cells showing an extreme bias towards the development of IL-4-producing Th2 cells and impaired Th1 differentiation. Indeed, these cytokine signaling defects may be responsible for many of the described clinical conditions, such as atopic dermatitis and elevated IgE levels (enhanced Th2), increased incidence of viral infections (IFN deficiency), infections by intracellular bacteria (IL-12 / Th1 deficiency) and infections by extracellular bacteria (IL-6 and IL-23 / Th17 deficiency).

[0016] Seven additional TYK2-deficient patients from five families and four different ethnic groups were identified by Kreins et al., pages 1-22, The Journal of Experimental Medicine, published 24 August 2015. These patients were homozygous for one of the five null mutations. By comparing the data obtained by Minegishi et al. with those obtained for seven additional TYK2-deficient patients, Kreins et al. concluded that the core clinical phenotype of TYK2 deficiency is mycobacterial and / or viral infections caused by impaired responses to IL-12 and IFN-α / β, whereas impaired IL-6 response and HIES do not appear to be unique features of TYK2 deficiency in humans.

[0017] Emerging evidence from genome-wide association studies suggests that single nucleotide polymorphisms (SNPs) in the TYK2 gene significantly influence susceptibility to autoimmune diseases.

[0018] Less efficient TYK2 variants are associated with systemic lupus erythematosus (SLE) (TYK2 rs2304256 and rsl2720270, Sigurdsson et al, 2005. Am. J. Hum. Genet. 76, 528-537; Graham et al, 2007. Rheumatology 46, 927-930; Hellquist et al, 2009. J. Rheumatol. 36, 1631-1638; Jarvinen et al, 2010. Exp. Dermatol. 19, 123-131) and multiple sclerosis (MS) (rs34536443, Ban et al, 2009. Eur. J. Hum. Genet. 17, 1309-1313; Mero et al, 2010. Exp. Dermatol. 19, 123-131). al, 2009. Eur. J. Hum. Genet. 18, 502-504), whereas predicted gain-of-function variants increase susceptibility to inflammatory bowel disease (IBD) (rs280519 and rs2304256, Sato et al, 2009. J. Clin. Immunol. 29, 815-825).

[0019] In humans, it has been reported that individuals expressing inactive variants of TYK2 are protected from multiple sclerosis and possibly other autoimmune disorders, and genome-wide association studies have shown that other variants of TYK2 are associated with autoimmune disorders such as Crohn's disease, psoriasis, systemic lupus erythematosus, and rheumatoid arthritis (see WO2014074661 and references cited therein), further demonstrating the importance of TYK2 in autoimmunity.

[0020] In support of the involvement of TYK2 in immunopathological disease processes, B10.D1 mice, which carry a missense mutation in the pseudokinase domain of TYK2 that results in the absence of the encoded TYK2 protein, have been shown to be resistant to both autoimmune arthritis (CIA) and experimental autoimmune encephalomyelitis (EAE) (Shaw et al, 2003. PNAS 100, 11594-11599; Spach et al, 2009. J. Immunol. 182, 7776-7783). Furthermore, recent studies have shown that TYK2 - / - showed that mice were completely resistant to MOG-induced EAE (Oyamada et al, 2009. J. Immunol. 183, 7539-7546). In these mice, resistance was accompanied by a lack of CD4 T cells infiltrating the spinal cord, an inability to signal through IL-12R and IL-23R, and therefore an inability to upregulate encephalitogenic levels of IFNγ and IL-17.

[0021] Overexpression of the TYK2 kinase has been implicated in the pathogenesis of several disease states, for example, elevated levels of TYK2 have been found in patients with progressive pulmonary sarcoidosis (Schischmanoff et al., Sarcoidosis Vasc. Diffuse., 2006, 23(2), 101-7).

[0022] Thus, available evidence strongly indicates that TYK2 plays an essential role in both innate and adaptive immunity. Lack of TYK2 expression is manifested in attenuated signaling of multiple inflammatory cytokines and a significant imbalance in T helper cell differentiation. Furthermore, evidence from genetic association studies supports TYK2 as a shared autoimmune disease susceptibility gene. Taken together, these reasons suggest TYK2 as a target for the treatment of inflammatory and autoimmune diseases.

[0023] Several JAK family inhibitors that may be useful in the medical field have been reported in the literature (Ghoreschi et al, 2009. Immunol Rev, 228: 273-287). Since inhibition of JAK2 can cause anemia, it has been proposed that selective TYK2 inhibitors that inhibit TYK2 with greater potency than JAK2 may have advantageous therapeutic properties (Ghoreschi et al, 2009. Nature Immunol. 4, 356-360).

[0024] Papp et al. (The New England Journal of Medicine, 12 September 2018, DOI: 10.1056 / NEJMoa1806382) disclose results from a Phase II clinical trial of the oral selective TYK2 inhibitor BMS-986165 in the treatment of psoriasis and conclude that the results show therapeutic benefit.

[0025] WO 2014 / 074661 (Bristol-Myers Squibb) discloses a class of pyridazine and triazine amides as TYK2 inhibitors useful in modulating IL-12, IL-23 and / or IFNα. It is suggested that the compounds may be useful in the treatment of a variety of inflammatory and autoimmune diseases.

[0026] WO 2016 / 027195 (Pfizer) discloses a series of aminopyrimidinyl compounds that have JAK kinase inhibitory activity, including activity against TYK2 kinase.

[0027] WO 2012 / 000970 (Cellzome) discloses a series of triazolopyridines as TYK2 kinase inhibitors. WO 2011 / 113802 (Roche) discloses a series of imidazopyridines as TYK2 kinase inhibitors. The properties of JAK kinases and their relevance as therapeutic targets are also disclosed in WO 2008 / 156726, WO 2009 / 155156, WO 2010 / 005841 and WO 2010 / 011375, all in the name of Merck.

[0028] WO 2010 / 055304 and EP 2634185 (both in the name of Sareum) disclose a family of substituted oxazolecarboxamides for use in the prevention or treatment of autoimmune diseases, particularly multiple sclerosis. The compounds disclosed in WO 2010 / 055304 are described as FLT3 kinase inhibitors. The kinase inhibitory effect of oxazolecarboxamides is also disclosed in International Patent Application WO 2008 / 139161 (Sareum).

[0029] WO 2015 / 032423 (Sareum) discloses the use of a subset of oxazolecarboxamide compounds as TYK2 kinase inhibitors. The compounds are said to be useful for the treatment of inflammatory and immunological disorders, such as autoimmune diseases.

[0030] WO 2018 / 073438 (Sareum) discloses the use of a subset of oxazolecarboxamide compounds with TYK2 kinase inhibitory activity for use in the treatment of T-cell lymphoblastic leukemia and cancers (such as hematopoietic cancers) that depend on the Janus kinase TYK2 for cancer cell survival.

[0031] Our previous International Patent Application No. PCT / EP2019 / 077118 discloses the compound 2-(2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)anilino]oxazole-4-carboxamide as a TYK2 kinase inhibitor with improved potency against TYK2 and improved pharmacokinetic properties. Summary of the Invention

[0032] It has now been found that the compound of formula (1), 2-(2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)anilino]oxazole-4-carboxamide, is capable of forming several different crystalline forms.

[0033] Thus, in a first embodiment (embodiment 1.0), the present invention provides a compound of formula (1): [ka] The present invention provides a substantially crystalline form of a compound having the formula:

[0034] The crystalline form may be, for example, any one of crystalline forms A, B, C and D as defined herein.

[0035] The above compounds may be variously referred to herein by terms such as "compounds having formula (1)", "compounds of formula (1)", "compound (1)", "compounds of formula (1)", "compound (1)" or "compounds of the invention", which terms are used synonymously herein.

[0036] In amorphous solids, the three-dimensional structure that is typically present in crystalline forms is absent; the positions of the molecules relative to one another in amorphous form are essentially random; see, for example, Hancock et al. J. Pharm. Sci. (1997), 86, 1).

[0037] The term "substantially crystalline" refers to a form of the compound of formula (1) that is 50% to 100% crystalline. Within this range, the compound of formula (1) may be at least 55% crystalline, or at least 60% crystalline, or at least 70% crystalline, or at least 80% crystalline, or at least 90% crystalline, or at least 95% crystalline, or at least 98% crystalline, or at least 99% crystalline, or at least 99.5% crystalline, or at least 99.9% crystalline, for example 100% crystalline.

[0038] The crystalline form of the compound of formula (1) preferably has a crystalline purity of at least 90%, more preferably at least 95%, i.e. at least 90% (more preferably at least 95%) of the compound is in a single crystalline form (e.g. Form A or Form B).

[0039] Crystalline forms of the compounds of the invention may be solvated (eg hydrated) or non-solvated (eg anhydrous).

[0040] The term "anhydrous" as used herein does not exclude the possibility that some water may be present on or within a compound (e.g., a crystal of a compound). For example, some water may be present on the surface of a compound (e.g., a crystal), or a small amount of water may be present within the body of a compound (e.g., a crystal). Typically, an anhydrous form contains less than 0.4 molecules of water per molecule of compound, more preferably less than 0.1 molecules of water, e.g., 0 molecules of water, per molecule of compound.

[0041] When the crystalline forms are hydrated, they may contain, for example, up to 3 molecules of water of crystallization, more usually up to 2 molecules of water, for example, 1 molecule of water or 2 molecules of water. Non-stoichiometric hydrates may also be formed, in which the number of molecules of water present is less than 1 or is otherwise a non-integer. For example, when less than 1 molecule of water is present, there may be, for example, 0.4, or 0.5, or 0.6, or 0.7, or 0.8, or 0.9 molecules of water per molecule of Compound (1).

[0042] The crystalline forms described herein, their crystals and their crystal structures form further aspects of the present invention.

[0043] Crystalline forms can be characterized using several techniques, including X-ray powder diffraction (XRPD), single crystal X-ray diffraction, differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). The behavior of crystals under conditions of varying humidity can be analyzed by gravimetric vapor sorption studies, such as dynamic vapor sorption (DVS).

[0044] The crystalline structure of a compound can be analyzed by the solid-state technique of X-ray powder diffraction (XRPD). XRPD can be performed according to conventional methods, such as those described herein (see examples below) and in "Introduction to X-ray Powder Diffraction", Ron Jenkins and Robert L. Snyder (John Wiley & Sons, New York, 1996). The presence of certain peaks (against random background noise) in the XRPD diffractogram indicates that the compound has a degree of crystallinity.

[0045] The powder X-ray pattern of a compound is characterized by the diffraction angle (2θ) and interplanar spacing (d) parameters of the X-ray diffraction spectrum, which are related by the Bragg equation, nλ=2d Sin θ, where n=1; λ=wavelength of X-ray radiation; d=interplanar spacing; and θ=diffraction angle. XRPD data for each of crystalline forms A, B, C, and D are shown below. Relative intensities should not be interpreted strictly as they may vary depending on the crystal growth direction, grain size, and measurement conditions. Furthermore, diffraction angles are usually meant to coincide within 2θ±0.2°.

[0046] Form A Form A is typically formed when a compound is dispersed in an aqueous solvent and conditions are created that allow crystallization to form A to occur. For example, form A can be prepared by dissolving or suspending an amorphous compound in an aqueous solvent such as water, 4:1 MeCN / water or 4:1 THF / water, and then subjecting the mixture to one or more (e.g., two) cycles of heating and cooling, whereby the mixture is heated to a moderately elevated temperature such as 50° C., held at the moderately elevated temperature for a period of time (e.g., at least several hours), cooled to a lower temperature near room temperature (e.g., about 25° C.), and allowed to equilibrate at the lower temperature for a period of time. Form A can also be prepared by dissolving compound (1) in a water-miscible solvent such as DMSO, and then slowly adding water, for example, over a period of at least an hour, more usually at least an hour and a half (e.g., about 2 hours).

[0047] Further methods for preparing crystalline form A are described below and in the Examples.

[0048] The XRPD diffractogram of Form A is shown in FIG.

[0049] The X-ray diffraction pattern of crystalline form A of compound (1) exhibits peaks of maximum intensity at the diffraction angles (2θ) listed in Table A-1, namely 23.1°, 12.3°, 16.7°, 20.7° and 13.7° (±0.2°). [Table 1]

[0050] Thus, in a further embodiment, the present invention provides: 1.1 The crystalline form according to embodiment 1.0 of Form A as defined herein. 1.2 A substantially crystalline form of compound of formula (1) (Form A) having an X-ray powder diffraction pattern characterised by the presence of major peaks at diffraction angles (2θ) of 23.1° and / or 12.3° and / or 16.7° and / or 20.7° and / or 13.7°. 1.3 A substantially crystalline form of the compound of formula (1) (Form A) having an X-ray powder diffraction pattern characterized by the presence of a major peak at a diffraction angle (2θ) of 23.1° (±0.2°). 1.4 A substantially crystalline form of the compound of formula (1) (Form A) having an X-ray powder diffraction pattern characterized by the presence of a major peak at a diffraction angle (2θ) of 12.3° (±0.2°). 1.5 A substantially crystalline form of the compound of formula (1) (Form A) having an X-ray powder diffraction pattern characterized by the presence of a major peak at a diffraction angle (2θ) of 16.7° (±0.2°). 1.6 A substantially crystalline form of the compound of formula (1) (Form A) having an X-ray powder diffraction pattern characterized by the presence of a major peak at a diffraction angle (2θ) of 20.7° (±0.2°). 1.7 A substantially crystalline form of the compound of formula (1) (Form A) having an X-ray powder diffraction pattern characterized by the presence of a major peak at a diffraction angle (2θ) of 13.7° (±0.2°). 1.8 A substantially crystalline form of compound of formula (1) (Form A), having an X-ray powder diffraction pattern characterised by the presence of major peaks at two or more, such as three or more, or four or more, in particular five, diffraction angles (2θ) selected from 23.1°, 12.3°, 16.7°, 20.7° and 13.7° (±0.2°).

[0051] The powder X-ray diffraction pattern of Form A of Compound (1) may also have smaller peaks present at the diffraction angles (2θ) listed in Table A-2, namely 21.9°, 20.8°, 10.7°, 23.6°, and 21.4° (±0.2°). [Table 2]

[0052] Thus, in a further embodiment, the present invention provides: 1.9 A substantially crystalline form of compound of formula (1) (Form A), having an X-ray powder diffraction pattern characterized by the presence of major peaks at diffraction angles (2θ) of 23.1° and / or 12.3° and / or 16.7° and / or 20.7° and / or 13.7° (e.g. at least four, more particularly at least five diffraction angles), and optionally one or more additional peaks at diffraction angles (2θ) selected from 21.9°, 20.8°, 10.7°, 23.6° and 21.4° (±0.2°). 1.10 A substantially crystalline form of compound of formula (1) (Form A), having an X-ray powder diffraction pattern characterized by the presence of major peaks at diffraction angles (2θ) of 23.1° and / or 12.3° and / or 16.7° and / or 20.7° and / or 13.7° (e.g. at least four, more particularly at least five diffraction angles), and optionally one or more additional peaks at diffraction angles (2θ) selected from 21.9°, 20.8° and 10.7° (±0.2°). 1.11 A substantially crystalline form of compound of formula (1) having an X-ray powder diffraction pattern characterized by the presence of major peaks at diffraction angles (2θ) of 23.1°, 12.3°, 16.7°, 20.7°, and 13.7°, and one or more additional peaks at diffraction angles (2θ) selected from 21.9°, 20.8°, and 10.7° (±0.2°) (Form A).

[0053] The powder X-ray diffraction pattern may be further characterized by the presence of additional peaks at diffraction angles (2θ) (±0.2°) as set forth in Table A-3. [Table 3]

[0054] Thus, in a further embodiment, the present invention provides: 1.12 A substantially crystalline form of the compound of formula (1) (Form A), having an X-ray powder diffraction pattern characterized by the presence of major peaks at diffraction angles (2θ) of 23.1°, 12.3°, 16.7°, 20.7°, and 13.7°; one or more additional peaks at diffraction angles (2θ) selected from 21.9°, 20.8°, 10.7°, 23.6°, and 21.4° (±0.2°); and optionally one or more additional peaks at diffraction angles (2θ) selected from 21.1°, 26.0°, 24.7°, 15.9°, and 17.9° (±0.2°). 1.13 A substantially crystalline form of Compound (1) (Form A) exhibiting peaks at diffraction angles set forth in Table 3 of the Examples section herein with a relative intensity of at least 15%. 1.14 A substantially crystalline form of Compound (1) (Form A), exhibiting peaks at diffraction angles corresponding to those in the powder X-ray diffraction pattern depicted in FIG. 1.15 A substantially crystalline form of Compound (1) (Form A), having an X-ray powder diffraction pattern substantially as shown in FIG.

[0055] The crystalline form of the present invention may also be characterized by Differential Scanning Calorimetry (DSC) and was found to exhibit an endothermic event with an onset temperature of about 182° C. and a peak at about 194° C., as shown in FIG. 4 of the accompanying drawings.

[0056] Thus, in a further embodiment, the present invention provides: 1.16 A substantially crystalline form of Compound (1) according to any one of embodiments 1.1 to 1.15 (Form A), having a DSC thermogram characterized by an endotherm with an onset temperature of about 182° C. and an onset and maximum at a peak of about 194° C. 1.17 A substantially crystalline form of compound (1) as defined in any one of embodiments 1.1 to 1.15 (Form A), having a DSC thermogram substantially as shown in Figure 4 of the accompanying drawings.

[0057] The present invention also provides a method for preparing crystalline form A. Thus, in a further embodiment, the present invention provides: 1.18 A process for preparing a substantially crystalline form (Form A) of Compound (1) as defined in any one of embodiments 1.1 to 1.17, comprising: (i) dispersing an amorphous form of compound (1) in an aqueous solvent selected from water, water / acetonitrile (e.g., 4:1 MeCN / water), and water / THF (e.g., 4:1 THF / water) to form a mixture; (ii) heating the mixture to a moderately elevated temperature in the range of 45-65° C. and holding the mixture at the moderately elevated temperature for at least 10 hours (e.g., 10-25 hours, e.g., about 17 hours); (iii) cooling or allowing the mixture to cool from the moderately elevated temperature to a lower temperature in the range of 15-30° C. (e.g., 20-30° C., e.g., about 25° C.) and holding the mixture at the lower temperature for at least 2 hours (e.g., 2-8 hours, e.g., about 4.5 hours); and (iv) optionally subjecting the mixture to further heating and cooling cycles, including heating the mixture to a moderately elevated temperature in the range of 45-65° C. and holding the mixture at the moderately elevated temperature for at least 10 hours (e.g., 10-25 hours, e.g., about 16 hours); cooling the mixture to a lower temperature in the range of 15-30° C. (e.g., 20-30° C., e.g., about 25° C.) and optionally holding the mixture at the lower temperature for at least 30 minutes (e.g., up to about 1 hour); and (v) isolating (e.g., by filtration) the crystalline form A of compound (1) thus formed. 1.19 A process for preparing a substantially crystalline form (Form A) of Compound (1) as defined in any one of embodiments 1.1 to 1.17, comprising: (i) dissolving compound (1) in a mixture of a water-miscible organic solvent (such as THF or acetonitrile) and water with heating to a moderately elevated temperature (e.g., 50° C. to 70° C., e.g., about 60° C.); (ii) adding a poor solvent such as a hydrocarbon or halogenated hydrocarbon (e.g., cyclohexane, heptane, benzotrifluoride, and 2-chlorobutane) at moderately elevated temperature; and (iii) cooling the resulting mixture to room temperature (e.g., about 25° C.) over a period of at least 1 hour (more usually at least 2 hours, e.g., about 3 hours); and (iv) optionally allowing the mixture to equilibrate for an additional period of at least 2 hours, more usually at least 5 hours, and more typically at least 10 hours; and (v) isolating crystalline form A. 1.20 A process for preparing a substantially crystalline form (Form A) of Compound (1) as defined in any one of embodiments 1.1 to 1.17, comprising: (i) dissolving compound (1) in a water-miscible organic solvent such as DMSO; and (ii) slowly adding water (e.g., over a period of at least 1 hour, more usually at least 1.5 hours (e.g., about 2 hours)) to precipitate compound (1) as crystalline form A.

[0058] Form B Form B can be formed by equilibrating the amorphous compound in hydrocarbon solvents, some halogenated hydrocarbon solvents (e.g., chlorobenzene, 2-chlorobutane, benzotrifluoride), some alcohols (methanol and IPA), some ketones (MIBK and MEK), some ethers (CPME, TBME, THF) and some aliphatic esters (iPrOAc) following the procedures described in the Examples.

[0059] Form B can also be formed by equilibrating crystalline form A in methyl ethyl ketone (MEK) following the procedure described in the examples.

[0060] In a further method of preparing Form B, the compound is dissolved in THF, a hydrocarbon or halogenated hydrocarbon anti-solvent (e.g., cyclohexane, heptane, benzotrifluoride or 2-chlorobutane) is added, and the mixture is subjected to equilibration as described in the Examples to obtain Form B.

[0061] The XRPD diffractogram of form B is shown in FIG.

[0062] The X-ray diffraction pattern of crystalline form B of compound (1) exhibits peaks of maximum intensity at the diffraction angles (2θ) listed in Table B-1, namely 23.2°, 16.7°, 22.6°, 26.6° and 12.0° (±0.2°). [Table 4]

[0063] Thus, in a further embodiment, the present invention provides: 2.1 The crystalline form according to embodiment 1.0 of Form B as defined herein. 2.2 A substantially crystalline form of compound of formula (1) having an X-ray powder diffraction pattern characterised by the presence of major peaks at diffraction angles (2θ) of 23.2° and / or 16.7° and / or 22.6° and / or 26.6° and / or 12.0° (Form B). 2.3 A substantially crystalline form of the compound of formula (1) (Form B) having an X-ray powder diffraction pattern characterized by the presence of a major peak at a diffraction angle (2θ) of 23.2° (±0.2°). 2.4 A substantially crystalline form of the compound of formula (1) (Form B) having an X-ray powder diffraction pattern characterized by the presence of a major peak at a diffraction angle (2θ) of 16.7° (±0.2°). 2.5 A substantially crystalline form of the compound of formula (1) (Form B) having an X-ray powder diffraction pattern characterized by the presence of a major peak at a diffraction angle (2θ) of 22.6° (±0.2°). 2.6 A substantially crystalline form of the compound of formula (1) (Form B) having an X-ray powder diffraction pattern characterized by the presence of a major peak at a diffraction angle (2θ) of 26.6° (±0.2°). 2.7 A substantially crystalline form of the compound of formula (1) (Form B) having an X-ray powder diffraction pattern characterized by the presence of a major peak at a diffraction angle (2θ) of 12.0° (±0.2°). 2.8 A substantially crystalline form of the compound of formula (1) (Form B), having an X-ray powder diffraction pattern characterised by the presence of major peaks at two or more, such as three or more, or four or more, especially five, diffraction angles (2θ) selected from 23.2°, 16.7°, 22.6°, 26.6° and 12.0° (±0.2°).

[0064] The powder X-ray diffraction pattern of Form B of Compound (1) may also have smaller peaks present at the diffraction angles (2θ) listed in Table B-2, namely 23.4°, 25.3°, 7.1°, 19.9°, and 27.8° (±0.2°). [Table 5]

[0065] Thus, in a further embodiment, the present invention provides: 2.9 A substantially crystalline form of compound of formula (1) having an X-ray powder diffraction pattern characterized by the presence of major peaks at diffraction angles (2θ) of 23.2° and / or 16.7° and / or 22.6° and / or 26.6° and / or 12.0° (e.g. at least four, more particularly at least five diffraction angles), and optionally one or more additional peaks at diffraction angles (2θ) selected from 23.4°, 25.3°, 7.1°, 19.9° and 27.8° (±0.2°) (Form B). 2.10 A substantially crystalline form of compound of formula (1) having an X-ray powder diffraction pattern characterized by the presence of major peaks at diffraction angles (2θ) of 23.2° and / or 16.7° and / or 22.6° and / or 26.6° and / or 12.0° (e.g., at least four, more particularly at least five diffraction angles), and optionally one or more additional peaks at diffraction angles (2θ) selected from 23.4°, 25.3° and 7.1° (±0.2°) (Form B). 2.11 A substantially crystalline form of the compound of formula (1) having an X-ray powder diffraction pattern characterized by the presence of major peaks at diffraction angles (2θ) of 23.2°, 16.7°, 22.6°, 26.6°, and 12.0°, and one or more additional peaks at diffraction angles (2θ) selected from 23.4°, 25.3°, and 7.1° (±0.2°) (Form B).

[0066] The powder X-ray diffraction pattern may be further characterized by the presence of additional peaks at diffraction angles (2θ) (±0.2°) as set forth in Table B-3, namely 14.2°, 27.0°, 24.1°, 28.9° and 14.5°. [Table 6]

[0067] Thus, in a further embodiment, the present invention provides: 2.12 A substantially crystalline form of the compound of formula (1) having an X-ray powder diffraction pattern characterized by the presence of major peaks at diffraction angles (2θ) 23.2°, 16.7°, 22.6°, 26.6°, and 12.0°; one or more additional peaks at diffraction angles (2θ) selected from 23.4°, 25.3°, 7.1°, 19.9°, and 27.8° (±0.2°); and optionally one or more additional peaks at diffraction angles (2θ) selected from 14.2°, 27.0°, 24.1°, 28.9°, and 14.5° (±0.2°). 2.13 A substantially crystalline form of Compound (1) (Form B) exhibiting peaks at diffraction angles set forth in Table 4 of the Examples section herein with a relative intensity of at least 15%. 2.14 A substantially crystalline form of Compound (1) (Form B), exhibiting peaks at diffraction angles corresponding to those in the powder X-ray diffraction pattern shown in FIG. 6. 2.15 A substantially crystalline form of Compound (1) (Form B), having an X-ray powder diffraction pattern substantially as shown in FIG.

[0068] The crystalline forms of the present invention can also be characterized by Differential Scanning Calorimetry (DSC). The DSC thermogram of Form B is characterized by endotherms with onset and maximum at about 230° C. and about 233° C., as shown in FIG.

[0069] Thus, in a further embodiment, the present invention provides: 2.16 A substantially crystalline form of compound (1) according to any one of embodiments 2.1 to 2.15 (Form B), having a DSC thermogram characterized by endotherms with onset and maximum at about 230° C. and about 233° C. 2.17 A substantially crystalline form of compound (1) as defined in any one of embodiments 2.1 to 2.15 (Form B), having a DSC thermogram substantially as shown in Figure 7 of the accompanying drawings.

[0070] The present invention also provides a method for preparing crystalline form B. Thus, in a further embodiment, the present invention provides: 2.18 A process for preparing a substantially crystalline form (Form B) of Compound (1) as defined in any one of embodiments 2.1 to 2.17, comprising: (i) Hydrocarbon solvents, halogenated hydrocarbon solvents (other than dichloromethane), methanol, isopropyl alcohol, aliphatic ketones (e.g., C 1-8 ketones), non-aromatic ethers (e.g., C 3-6 dispersing an amorphous form of compound (1) in a solvent selected from dialkyl and alkyl cycloalkyl ethers and THF, and isopropyl acetate to form a mixture; (ii) heating the mixture to a moderately elevated temperature in the range of 45-65° C. and holding the mixture at the moderately elevated temperature for at least 10 hours (e.g., 10-25 hours, e.g., about 17 hours); (iii) cooling or allowing the mixture to cool from the moderately elevated temperature to a lower temperature in the range of 15-30° C. (e.g., 20-30° C., e.g., about 25° C.) and holding the mixture at the lower temperature for at least 2 hours (e.g., 2-8 hours, e.g., about 4.5 hours); and (iv) optionally subjecting the mixture to further heating and cooling cycles, including heating the mixture to a moderately elevated temperature in the range of 45-65° C. and holding the mixture at the moderately elevated temperature for at least 10 hours (e.g., 10-25 hours, e.g., about 16 hours); cooling the mixture to a lower temperature in the range of 15-30° C. (e.g., 20-30° C., e.g., about 25° C.) and optionally holding the mixture at the lower temperature for at least 30 minutes (e.g., up to about 1 hour); and (v) isolating (e.g., by filtration) the crystalline form B of compound (1) thus formed. 2.19 A process for preparing a substantially crystalline form (Form B) of Compound (1) as defined in any one of embodiments 2.1 to 2.17, comprising: (i) dispersing crystalline form A of compound (1) in methyl ethyl ketone (MEK) to form a mixture; (ii) heating the mixture to a moderately elevated temperature in the range of 45-65° C. and holding the mixture at the moderately elevated temperature for at least 10 hours (e.g., 10-25 hours, e.g., about 21 hours); (iii) cooling or allowing the mixture to cool from the moderately elevated temperature to a lower temperature in the range of 15-30° C. (e.g., 20-30° C., e.g., about 25° C.) and holding the mixture at the lower temperature for at least 2 hours (e.g., 2-8 hours, e.g., about 4 hours); and (iv) optionally subjecting the mixture to further heating and cooling cycles, including heating the mixture to a moderately elevated temperature in the range of 45-65° C. and holding the mixture at the moderately elevated temperature for at least 10 hours (e.g., 10-25 hours, e.g., about 16 hours); cooling the mixture to a lower temperature in the range of 15-30° C. (e.g., 20-30° C., e.g., about 25° C.) and optionally holding the mixture at the lower temperature for at least 30 minutes (e.g., up to about 1 hour); and (v) isolating (e.g., by filtration) the crystalline form B of compound (1) thus formed. 2.20 A process for preparing a substantially crystalline form (Form B) of Compound (1) as defined in any one of embodiments 2.1 to 2.17, comprising: (i) dispersing a solid form of compound (1) in methyl ethyl ketone (MEK) to form a mixture; (ii) subjecting the mixture to an equilibration procedure comprising periods of heating and cooling the mixture until a suspension of crystalline form B is formed; and optionally, further equilibrating the mixture until a desired level of polymorphic purity is achieved. 2.21 The method of embodiment 2.20, wherein the solid form of Compound (1) dispersed in MEK is crystalline Form A.

[0071] Form C Crystalline Form C of Compound (1) can be formed by dispersing amorphous Compound (1) in a solvent selected from nitromethane, ethanol, dichloromethane and acetonitrile and subjecting the resulting mixture to the equilibration procedure described in Example 2.

[0072] The XRPD diffractogram of Form C is shown in FIG.

[0073] The X-ray diffraction pattern of crystalline form C of compound (1) exhibits peaks of maximum intensity at the diffraction angles (2θ) listed in Table C-1, namely 12.8°, 17.8°, 22.9°, 24.3° and 8.5° (±0.2°). [Table 7]

[0074] Thus, in a further embodiment, the present invention provides: 3.1 The crystalline form according to embodiment 1.0 of Form C as defined herein. 3.2 A substantially crystalline form of compound of formula (1) having an X-ray powder diffraction pattern characterised by the presence of major peaks at diffraction angles (2θ) of 12.8° and / or 17.8° and / or 22.9° and / or 24.3° and / or 8.5° (Form C). 3.3 A substantially crystalline form of the compound of formula (1) (Form C) having an X-ray powder diffraction pattern characterized by the presence of a major peak at a diffraction angle (2θ) of 12.8° (±0.2°). 3.4 A substantially crystalline form of the compound of formula (1) (Form C) having an X-ray powder diffraction pattern characterized by the presence of a major peak at a diffraction angle (2θ) of 17.8° (±0.2°). 3.5 A substantially crystalline form of the compound of formula (1) (Form C) having an X-ray powder diffraction pattern characterized by the presence of a major peak at a diffraction angle (2θ) of 22.9° (±0.2°). 3.6 A substantially crystalline form of the compound of formula (1) (Form C) having an X-ray powder diffraction pattern characterized by the presence of a major peak at a diffraction angle (2θ) of 24.3° (±0.2°). 3.7 A substantially crystalline form of the compound of formula (1) (Form C) having an X-ray powder diffraction pattern characterized by the presence of a major peak at a diffraction angle (2θ) of 8.5° (±0.2°). 3.8 A substantially crystalline form of compound of formula (1) having an X-ray powder diffraction pattern characterised by the presence of major peaks at two or more, such as three or more, or four or more, especially five, diffraction angles (2θ) selected from 12.8°, 17.8°, 22.9°, 24.3° and 8.5° (±0.2°) (Form C).

[0075] The powder X-ray diffraction pattern of Form C of Compound (1) may also have smaller peaks present at the diffraction angles (2θ) listed in Table C-2, namely 13.0°, 20.1°, 16.5°, 26.1°, and 22.4° (±0.2°). [Table 8]

[0076] Thus, in a further embodiment, the present invention provides: 3.9 A substantially crystalline form of compound of formula (1) having an X-ray powder diffraction pattern characterized by the presence of major peaks at diffraction angles (2θ) of 12.8° and / or 17.8° and / or 22.9° and / or 24.3° and / or 8.5° (e.g. at least four, more particularly at least five diffraction angles), and optionally one or more additional peaks at diffraction angles (2θ) selected from 13.0°, 20.1°, 16.5°, 26.1° and 22.4° (±0.2°) (Form C). 3.10 A substantially crystalline form of compound of formula (1) having an X-ray powder diffraction pattern characterized by the presence of major peaks at diffraction angles (2θ) of 12.8° and / or 17.8° and / or 22.9° and / or 24.3° and / or 8.5° (e.g. at least four, more particularly at least five diffraction angles), and optionally one or more additional peaks at diffraction angles (2θ) selected from 13.0°, 20.1° and 16.5° (±0.2°) (Form C). 3.11 A substantially crystalline form of the compound of formula (1) having an X-ray powder diffraction pattern characterized by the presence of major peaks at diffraction angles (2θ) of 12.8°, 17.8°, 22.9°, 24.3°, and 8.5°, and one or more additional peaks at diffraction angles (2θ) selected from 13.0°, 20.1°, and 16.5° (±0.2°) (Form C).

[0077] The powder X-ray diffraction pattern may be further characterized by the presence of additional peaks at diffraction angles (2θ) (±0.2°) as set forth in Table C-3, namely 23.1°, 24.7°, 18.8°, 25.0° and 25.3° (±0.2°). [Table 9]

[0078] Thus, in a further embodiment, the present invention provides: 3.12 A substantially crystalline form of the compound of formula (1) having an X-ray powder diffraction pattern characterized by the presence of major peaks at diffraction angles (2θ) of 12.8°, 17.8°, 22.9°, 24.3°, and 8.5°; one or more additional peaks at diffraction angles (2θ) selected from 13.0°, 20.1°, 16.5°, 26.1°, and 22.4° (±0.2°); and optionally one or more additional peaks at diffraction angles (2θ) selected from 23.1°, 24.7°, 18.8°, 25.0°, and 25.3° (±0.2°). 3.13 A substantially crystalline form of Compound (1) (Form C) exhibiting peaks at diffraction angles set forth in Table 5 of the Examples section herein with a relative intensity of at least 15%. 3.14 A substantially crystalline form of Compound (1) (Form C), exhibiting peaks at diffraction angles corresponding to those in the powder X-ray diffraction pattern depicted in FIG. 3.15 A substantially crystalline form of Compound (1) (Form C), having an X-ray powder diffraction pattern substantially as shown in FIG.

[0079] The crystalline forms of the present invention can also be characterized by differential scanning calorimetry (DSC). Crystalline form C of compound (1) was analyzed by DSC and found to exhibit a thermogram as shown in Figure 10 of the accompanying drawings.

[0080] Form D Crystalline Form D of Compound (1) can be formed by dispersing amorphous Compound (1) in ethyl acetate and subjecting the resulting mixture to the equilibration procedure described in Example 2.

[0081] The XRPD diffractogram of form D is shown in FIG.

[0082] The X-ray diffraction pattern of crystalline form D of compound (1) exhibits peaks of maximum intensity at the diffraction angles (2θ) listed in Table D-1, namely 13.9°, 21.4°, 21.2°, 23.4° and 16.6° (±0.2°). [Table 10]

[0083] Thus, in a further embodiment, the present invention provides: 4.1 The crystalline form according to embodiment 1.0 of Form D as defined herein. 4.2 A substantially crystalline form of compound of formula (1) having an X-ray powder diffraction pattern characterised by the presence of major peaks at diffraction angles (2θ) of 13.9° and / or 21.4° and / or 21.2° and / or 23.4° and / or 16.6° (Form D). 4.3 A substantially crystalline form of the compound of formula (1) having an X-ray powder diffraction pattern characterized by the presence of a major peak at a diffraction angle (2θ) of 13.9° (±0.2°) (Form D). 4.4 A substantially crystalline form of the compound of formula (1) (Form D) having an X-ray powder diffraction pattern characterized by the presence of a major peak at a diffraction angle (2θ) of 21.4° (±0.2°). 4.5 A substantially crystalline form of the compound of formula (1) (Form D) having an X-ray powder diffraction pattern characterized by the presence of a major peak at a diffraction angle (2θ) of 21.2° (±0.2°). 4.6 A substantially crystalline form of the compound of formula (1) (Form D) having an X-ray powder diffraction pattern characterized by the presence of a major peak at a diffraction angle (2θ) of 23.4° (±0.2°). 4.7 A substantially crystalline form of the compound of formula (1) (Form D) having an X-ray powder diffraction pattern characterized by the presence of a major peak at a diffraction angle (2θ) of 16.6° (±0.2°). 4.8 A substantially crystalline form of compound of formula (1) having an X-ray powder diffraction pattern characterised by the presence of major peaks at two or more, such as three or more, or four or more, especially five, diffraction angles (2θ) selected from 13.9°, 21.4°, 21.2°, 23.4° and 16.6° (±0.2°) (Form D).

[0084] The powder X-ray diffraction pattern of Form D of Compound (1) may also have smaller peaks present at the diffraction angles (2θ) listed in Table D-2, namely 16.1°, 24.1°, 18.0°, 22.5°, and 13.0° (±0.2°). [Table 11]

[0085] Thus, in a further embodiment, the present invention provides: 4.9 A substantially crystalline form of compound of formula (1) (Form D), having an X-ray powder diffraction pattern characterized by the presence of major peaks (e.g. at least four, more particularly at least five diffraction angles) at diffraction angles (2θ) of 13.9° and / or 21.4° and / or 21.2° and / or 23.4° and / or 16.6° as defined above, and optionally one or more additional peaks at diffraction angles (2θ) selected from 16.1°, 24.1°, 18.0°, 22.5° and 13.0° (±0.2°). 4.10 A substantially crystalline form of compound of formula (1) (Form D), having an X-ray powder diffraction pattern characterized by the presence of major peaks (e.g. at least four, more particularly at least five diffraction angles) at diffraction angles (2θ) of 13.9° and / or 21.4° and / or 21.2° and / or 23.4° and / or 16.6° as defined above, and optionally one or more additional peaks at diffraction angles (2θ) selected from 16.1°, 24.1° and 18.0° (±0.2°). 4.11 A substantially crystalline form of compound of formula (1) having an X-ray powder diffraction pattern characterized by the presence of major peaks at diffraction angles (2θ) of 13.9°, 21.4°, 21.2°, 23.4°, and 16.6°, and one or more additional peaks at diffraction angles (2θ) selected from 16.1°, 24.1°, and 18.0° (±0.2°) (Form D).

[0086] The powder X-ray diffraction pattern may be further characterized by the presence of additional peaks at diffraction angles (2θ) (±0.2°) as set forth in Table D-3, namely 19.9°, 6.9°, 27.7°, 25.2° and 26.4°. [Table 12]

[0087] Thus, in a further embodiment, the present invention provides: 4.12 A substantially crystalline form of compound of formula (1) having an X-ray powder diffraction pattern characterized by the presence of major peaks at diffraction angles (2θ) of 13.9°, 21.4°, 21.2°, 23.4°, and 16.6°; one or more additional peaks at diffraction angles (2θ) selected from 16.1°, 24.1°, 18.0°, 22.5°, and 13.0° (±0.2°); and optionally one or more additional peaks at diffraction angles (2θ) selected from 19.9°, 6.9°, 27.7°, 25.2°, and 26.4° (±0.2°). 4.13 A substantially crystalline form of Compound (1) (Form D) exhibiting peaks at diffraction angles set forth in Table 6 of the Examples section herein with a relative intensity of at least 15%. 4.14 A substantially crystalline form of Compound (1) (Form D), exhibiting peaks at diffraction angles corresponding to those in the powder X-ray diffraction pattern shown in FIG. 4.15 A substantially crystalline form of Compound (1) (Form D), having an X-ray powder diffraction pattern substantially as shown in FIG.

[0088] Crystalline form D may also be characterized by differential scanning calorimetry (DSC) and has a thermogram substantially as shown in FIG.

[0089] Isotopes The crystalline forms of the compounds of formula (1) defined in any one of embodiments 1.0 to 4.15 may include one or more isotopic substitutions, and a reference to a particular element includes within its scope all isotopes of that element. For example, a reference to hydrogen includes within its scope all isotopes of that element. 1 H,2 H(D) and 3 Similarly, references to carbon and oxygen each include within their scope 12 C. 13 C and 14 C and 16 O and 18 Contains O.

[0090] Similarly, reference to a particular functional group also includes isotopic variations within its scope unless the context dictates otherwise.

[0091] The isotope may be radioactive or non-radioactive. In one general embodiment of the invention (embodiment 5.1), the crystalline form of the compound of formula (1) as defined in any one of embodiments 1.0 to 4.15 does not contain a radioactive isotope. Such compounds are preferred for therapeutic use. However, in another embodiment (embodiment 5.2), the crystalline form of the compound of formula (1) as defined in any one of embodiments 1.0 to 4.15 may contain one or more radioactive isotopes. Compounds containing such radioactive isotopes may be useful in diagnostic contexts.

[0092] biological activity The crystalline forms of the compound of formula (1) as defined in any one of embodiments 1.0 to 5.2 are potent and selective inhibitors of TYK2 kinase. The TYK2 kinase inhibitory activity of the compounds can be determined using the assays described in the Examples below.

[0093] The experimental data obtained for compound (1) demonstrates that this compound has significant advantages over the structurally most similar compound (compound B) in WO 2015 / 032423. Thus, compound (1) is more active than the closest known compound (compound B) in the TYK2 kinase inhibition assay, and both have higher selectivity for TYK2 over JAK1, JAK2 and JAK3 kinases than compound B. Furthermore, compound (1) exhibits reduced hERG risk compared to comparative compound B of the prior art. Furthermore, in hepatocyte stability assays, compound (1) exhibited a reduced clearance rate and a consequently longer half-life than comparative compound B.

[0094] Taken together, the data indicate that compound (1) is not only a more potent and more selective TYK2 kinase inhibitor than comparative compound B, but also possesses better pharmacokinetic properties than compound B.

[0095] The TYK2 kinase inhibitory activity of the crystalline forms of the compounds of formula (1) can be utilized in a variety of methods for treating diseases in which TYK2 plays a role in the development or progression of the disease. The various uses of the compounds of formula (1) typically involve contacting the compounds with TYK2 kinase. Inhibition of TYK2 kinase can occur either in vitro or in vivo.

[0096] Thus, in a further embodiment, the present invention provides: 6.1 A crystalline form of the compound of formula (1) as defined in any one of embodiments 1.0 to 5.2 for use as an inhibitor of TYK2 kinase. 6.2 A crystalline form of the compound of formula (1) as defined in any one of embodiments 1.0 to 5.2 for use in medicine.

[0097] Inhibition of TYK2 kinase preferably occurs in vivo as part of a therapeutic treatment of a disease or condition in which TYK2 kinase is involved.

[0098] The compound of formula (1) is a selective TYK2 inhibitor, and is significantly more active against TYK2 than against JAK2 and JAK3 kinases. The compound has relatively low activity against a wide range of other kinases, particularly those that are generally recognized as targets for anti-cancer therapy. Thus, for example, the compound has relatively low activity against Chk1 kinase, Aurora kinase, PKB (Akt) kinase, and cyclin-dependent kinase (CDK kinase) that are involved in cell cycle progression. The lack of activity against kinases that are typically considered to be anti-cancer targets is beneficial in a compound that can be used, for example, for chronic treatment of inflammatory and autoimmune diseases.

[0099] Based on their TYK2 inhibitory activity, it is envisioned that the crystalline forms of the compound of formula (1) defined in any one of embodiments 1.0 to 5.2 are useful for treating at least some of the diseases and disorders discussed below, including inflammatory diseases or conditions, immunological diseases or conditions, autoimmune diseases, allergic diseases or disorders, transplant rejection (allograft rejection), graft-versus-host disease, and for treating sepsis and septic shock.

[0100] In the context of the present invention, an autoimmune disease is a disease that is at least partially triggered by the body's immune response to its own components, such as proteins, lipids or DNA. Examples of organ-specific autoimmune disorders are insulin-dependent diabetes mellitus (type I), which affects the pancreas; Hashimoto's thyroiditis and Graves' disease, which affect the thyroid gland; pernicious anemia, which affects the stomach; Cushing's disease and Addison's disease, which affect the adrenal glands; chronic active hepatitis, which affects the liver; polycystic ovarian syndrome (PCOS), celiac disease, psoriasis, inflammatory bowel disease (IBD), lupus nephritis (kidney inflammation) and ankylosing spondylitis. Examples of non-organ-specific autoimmune disorders are rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus and myasthenia gravis. Type I diabetes results from the selective attack of autoreactive T cells on insulin-secreting beta cells in the islets of Langerhans. Other inflammatory or immune diseases and disorders that may benefit from treatment with the compounds of the invention include skin inflammation due to radiation exposure; asthma; allergic inflammation; chronic inflammation; inflammatory eye disease; dry eye syndrome (DES, also known as keratoconjunctivitis sicca or dysfunctional tear syndrome); uveitis (e.g., chronic progressive or relapsing forms of non-infectious uveitis); alopecia areata; primary biliary cirrhosis; and systemic sclerosis; Rheumatoid arthritis (RA) is a chronic, progressive, debilitating inflammatory disease that affects approximately 1% of the world's population. RA is a symmetric polyarticular arthritis that primarily affects the small joints of the hands and feet. In addition to inflammation of the synovium, the joint lining, an aggressive front of tissue called pannus invades and destroys local joint structures (Firestein 2003, Nature 423:356-361).

[0101] Inflammatory bowel disease (IBD) is characterized by chronic relapsing intestinal inflammation. IBD is subdivided into Crohn's disease and ulcerative colitis phenotypes. Crohn's disease most frequently involves the terminal ileum and colon and is transmural and discontinuous. In contrast, in ulcerative colitis, inflammation is continuous and limited to the mucosal layer of the rectum and colon. In approximately 10% of cases limited to the rectum and colon, a clear classification of Crohn's disease or ulcerative colitis cannot be made and is referred to as "indeterminate colitis." Both diseases involve extraintestinal inflammation of the skin, eyes, or joints. Neutrophil-induced damage can be prevented by the use of neutrophil migration inhibitors (Asakura et al., 2007, World J. Gastroenterol. 13(15):2145-9).

[0102] Psoriasis is a chronic inflammatory skin disease that affects approximately 2% of the population. It is characterized by red, scaly patches of skin, usually found on the scalp, elbows and knees, and may be associated with severe arthritis. The lesions are caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis (Schon et al, 2005, New Engl. J. Med. 352:1899-1912).

[0103] Systemic lupus erythematosus (SLE) is a chronic inflammatory disease caused by T cell-mediated B cell activation, leading to glomerulonephritis and renal failure. In the early stages, human SLE is characterized by the expansion of long-lasting autoreactive CD4+ memory cells (D'Cruz et al., 2007, Lancet 369(9561):587-596).

[0104] Transplant rejection (allograft rejection) includes, but is not limited to, acute and chronic allograft rejection after transplantation of, for example, kidney, heart, liver, lung, bone marrow, skin and cornea. T cells are known to play a central role in the specific immune response of allograft rejection. Hyperacute, acute and chronic organ transplant rejection may be treated. Hyperacute rejection occurs within minutes after transplantation. Acute rejection generally occurs within 6 to 12 months after transplantation. Hyperacute and acute rejection are typically reversible when treated with immunosuppressants. Chronic rejection, characterized by gradual loss of organ function, is an ongoing concern for transplant recipients as it can occur any time after transplantation.

[0105] Graft-versus-host disease (GVDH) is a major complication in allogeneic bone marrow transplantation (BMT) that is caused by donor T cells that recognize and react to recipient differences in the histocompatibility complex system, resulting in significant morbidity and mortality.

[0106] Pulmonary sarcoidosis is a relatively rare inflammatory disorder of unknown cause that has been shown to be associated with elevated levels of TYK2 and typically occurs in adults between the ages of 20 and 50. Pulmonary sarcoidosis is characterized by small masses or granulomas in the lungs that generally heal and resolve spontaneously. However, in the case of granulomas that do not heal, the tissue remains inflamed and may become scarred or fibrotic. Pulmonary sarcoidosis can develop into pulmonary fibrosis, which can distort the structure of the lungs and impede breathing.

[0107] Thus, in a further embodiment, the present invention provides: 6.3 A method of treating a disease or condition in a subject in need of such treatment, wherein the disease or condition is selected from an autoimmune disease, an inflammatory disease or condition, an immunological disease or condition, an allergic disease or disorder, transplant rejection and graft-versus-host disease, or selected from sepsis and septic shock disease, and the disease or condition is amenable to TYK2 inhibition, the method comprising administering to the subject an effective TYK2 inhibitory amount of a crystalline form of a compound of Formula (1) as defined in any one of embodiments 1.0 to 5.2. 6.4 A crystalline form of the compound of formula (1) as defined in any one of embodiments 1.0 to 5.2 for use in the treatment of a disease or condition selected from an autoimmune disease, an inflammatory disease or condition, an immunological disease or condition, an allergic disease or disorder, transplant rejection and graft versus host disease, or for use in the treatment of sepsis or septic shock, wherein the disease or condition is amenable to TYK2 inhibition. 6.5 Use of a crystalline form of the compound of formula (1) as defined in any one of embodiments 1.0 to 5.2 for the manufacture of a medicament for the treatment of a disease or condition selected from an autoimmune disease, an inflammatory disease or condition, an immunological disease or condition, an allergic disease or disorder, transplant rejection and graft versus host disease, or for use in the treatment of sepsis or septic shock, wherein the disease or condition is amenable to TYK2 inhibition. 6.6 A method of treating an autoimmune disease in a subject in need of such treatment, comprising administering to the subject an effective TYK2-inhibiting amount of a crystalline form of a compound of formula (1) as defined in any one of embodiments 1.0 to 5.2 to inhibit TYK2 kinase in the subject and thereby block or reduce the extent of the inflammatory process associated with the autoimmune disease. 6.7 A crystalline form of the compound of formula (1) as defined in any one of embodiments 1.0 to 5.2 for use in a method of treating an autoimmune disease in a subject in need thereof, the method comprising administering to the subject an effective TYK2 inhibitory amount of the compound to inhibit TYK2 kinase in the subject, thereby blocking or reducing the extent of the inflammatory process associated with the autoimmune disease. 6.8 Use of a crystalline form of the compound of formula (1) as defined in any one of embodiments 1.0 to 5.2 for the manufacture of a medicament for treating an autoimmune disease in a subject in need thereof, wherein the treatment comprises administering to the subject an effective TYK2 inhibitory amount of the compound to inhibit TYK2 kinase in the subject, thereby blocking or reducing the extent of the inflammatory process associated with the autoimmune disease. 6.9 A method of treating a disease or condition in a subject in need thereof, wherein the disease or condition is characterized by, or caused (at least in part) by, or associated with overexpression (elevated expression) of TYK2 kinase, comprising administering to the subject an effective TYK2-inhibiting amount of a compound of any one of embodiments 1.0-5.2. 6.10 A crystalline form of the compound of formula (1) as defined in any one of embodiments 1.0 to 5.2 for use in treating a disease or condition in a subject in need thereof, wherein the disease is characterized by, caused (at least in part) by, or associated with overexpression (elevated expression) of TYK2 kinase. 6.11 The method, compound for use or use according to any one of embodiments 6.3 to 6.10, wherein the disease or condition is an autoimmune disease. 6.12 The method, compound for use or use according to any one of embodiments 6.3 to 6.10, wherein the disease or condition is an autoimmune disease other than multiple sclerosis. 6.13 The method, compound for use or use according to any one of embodiments 6.3 to 6.10, wherein the disease or condition is psoriasis. 6.14 The method, compound for use or use according to any one of embodiments 6.3 to 6.10, wherein the disease or condition is psoriatic arthritis. 6.15 The method of embodiment 6.3, wherein the disease or condition is multiple sclerosis.

[0108] The activity of the compounds of formula (1) and their crystalline forms as TYK2 inhibitors can be measured using the assays described in the Examples below, and the level of activity exhibited by a given compound is expressed as the IC 50 The compound of formula (1) has an IC value for TYK2 kinase of 1.9 nanomolar. 50 It has a value.

[0109] An advantage of the compounds of formula (1) is that they exhibit selectivity for TYK2 kinase compared to other kinases of the JAK family.

[0110] For example, in biochemical assays, the compound of formula (1) has approximately 25-fold selectivity for TYK2 over JAK2, and 110-fold selectivity for TYK2 over JAK3.

[0111] The suitability of the crystalline forms of the compounds of formula (1) defined in any one of embodiments 1.0 to 5.2 for use in treating psoriasis can be determined by testing their effect on imiquimod-induced psoriasis-like skin inflammation in mice: see, for example, Mori et al., Kobe J.Med.Sci., Vol.62, No.4, pp.E79-E88,2016; van der Fits et al., The Journal of Immunology, 2009;182:5836-5845; and Lin et al., PLOS ONE | DOI:10.1371 / journal.pone.0137890 September 10,2015. Thus, imiquimod can be applied topically to mice (e.g., to the ears of the mice) to induce psoriasis-like inflammation and desquamation, and the levels of inflammation and desquamation in mice (or regions of the mouse body) treated with a crystalline form of the compound of formula (1) or a control not containing imiquimod can be compared.

[0112] Method for preparing compounds of formula (1) Compounds of formula (1) may be prepared by the methods described in the following paragraphs and in the examples below.

[0113] Compounds of formula (1) can be prepared by the sequence of reactions shown in Scheme 1. [ka]

[0114] In the first step of the reaction sequence, 2,6-dichlorobenzoyl chloride (10) is reacted with aminomalononitrile (11) (e.g., its p-toluenesulfonate salt) in a polar aprotic solvent such as N-methylpyrrolidone (NMP) to give amino-oxazole nitrile (12). The reaction is typically carried out at elevated temperatures, for example in the range of 90° C. to 115° C.

[0115] The aminooxazole nitrile (12) is converted to the corresponding bromo compound (13) by the metal-free Sandmeyer method using tertiary butyl nitrite as the diazotizing agent in the presence of a halogen donor compound such as bromo(trimethyl)silane in dibromomethane. The reaction is typically carried out under a protective (e.g. nitrogen) atmosphere at a temperature of about 0°C. Alternatively, instead of using the metal-free Sandmeyer method, a copper catalyst can be used. For example, tertiary butyl nitrite can be used in the presence of CuBr2 instead of bromo(trimethyl)silane.

[0116] Bromo compound (13) is reacted with substituted aniline (14) in a Buchwald-Hartwig palladium catalyzed amination procedure to give cyano intermediate (15). The reaction uses a palladium(0) catalyst such as bis(dibenzylideneacetone)-palladium(0) (Pd(dba)2) in the presence of a suitable phosphine ligand such as 1,1'-ferrocenediyl-bis(diphenyl-phosphine) (dppf) or (5-diphenyl-phosphanyl-9,9-dimethyl-xanthen-4-yl)-diphenyl-phosphane and a base such as potassium carbonate or cesium carbonate in a polar aprotic solvent such as dioxane. The reaction is typically carried out at elevated temperature (e.g. 95-125°C) using microwave heating, for example in a sealed tube.

[0117] The cyano intermediate (15) is hydrolyzed under mildly acidic conditions (eg, using sulfuric acid or a mixture of trifluoroacetic acid and sulfuric acid at a temperature between about 0° C. and 20° C.) to provide the compound of formula (1).

[0118] Pharmaceutical preparations While it is possible for an active compound to be administered alone, it is preferable to present at least one active compound of the invention as a pharmaceutical composition (e.g., a formulation) comprising one or more pharma- ceutically acceptable excipients, such as carriers, adjuvants, diluents, fillers, buffers, stabilizers, preservatives, lubricants, or other materials well known to those skilled in the art, and, optionally, other therapeutic or prophylactic agents.

[0119] The term "pharmacologically acceptable" as used herein refers to compounds, materials, compositions, and / or dosage forms that are suitable for use in contact with the tissues of a subject (e.g., a human) without undue toxicity, irritation, allergic response, or other problem or complication, within the scope of sound medical judgment, commensurate with a reasonable benefit / risk ratio. Each excipient must also be "acceptable" in the sense of being compatible with the other ingredients of the formulation.

[0120] Thus, in a further embodiment, the present invention provides: 7.1 A pharmaceutical composition comprising a crystalline form of a compound of formula (1) as defined in any one of embodiments 1.0 to 5.2 and a pharma- ceutically acceptable excipient.

[0121] In further embodiments, the following is provided: 7.2 A pharmaceutical composition according to embodiment 7.1 comprising from about 1% (w / w) to about 95% (w / w) of a crystalline form of the compound of formula (1) as defined in any one of embodiments 1.0 to 5.2, and from 99% (w / w) to 5% (w / w) of a pharma- ceutically acceptable excipient or combination of excipients, and optionally one or more further therapeutically active ingredients. 7.3 A pharmaceutical composition according to embodiment 7.2, comprising from about 5% (w / w) to about 90% (w / w) of a crystalline form of the compound of formula (1) as defined in any one of embodiments 1.0 to 5.2, and from 95% (w / w) to 10% of a pharmaceutical excipient or combination of excipients, and optionally one or more further therapeutically active ingredients. 7.4 A pharmaceutical composition according to embodiment 7.3, comprising from about 10% (w / w) to about 90% (w / w) of a crystalline form of the compound of formula (1) as defined in any one of embodiments 1.0 to 5.2, and from 90% (w / w) to 10% of a pharmaceutical excipient or combination of excipients. 7.5 The pharmaceutical composition according to embodiment 7.4, comprising from about 20% (w / w) to about 90% (w / w) of a crystalline form of the compound of formula (1) as defined in any one of embodiments 1.0 to 5.2, and from 80% (w / w) to 10% of a pharmaceutical excipient or combination of excipients. 7.6 The pharmaceutical composition according to embodiment 4.5, comprising from about 25% (w / w) to about 80% (w / w) of a crystalline form of the compound of formula (1) as defined in any one of embodiments 1.0 to 5.2, and from 75% (w / w) to 20% of a pharmaceutical excipient or combination of excipients.

[0122] It will be appreciated that pharmaceutical compositions comprising a crystalline form of the compound of formula (1) will typically be solid compositions such as tablets, capsules, caplets, pills, lozenges, sprays, powders, granules, sublingual tablets, wafers, or patches and buccal patches, or liquid compositions such as suspensions in which the active compound is in solid form.

[0123] Thus, in a further embodiment, the present invention provides: 7.7 A pharmaceutical composition according to any one of embodiments 7.1 to 7.6, suitable for oral administration. 7.8 The pharmaceutical composition according to embodiment 7.7, selected from a tablet, capsule, caplet, pill, lozenge, powder, granule, suspension, sublingual tablet, wafer or patch, and a buccal patch. 7.9 The pharmaceutical composition according to embodiment 7.8, selected from a tablet and a capsule. 7.10 The pharmaceutical composition according to embodiment 7.9, wherein the crystalline form of the compound of formula (1) is Form B as defined in any one of embodiments 2.1 to 2.17. 7.11 The pharmaceutical composition according to any one of embodiments 7.1 to 7.6, which is suitable for parenteral administration and is in the form of a suspension for injection or infusion. 7.12 The pharmaceutical composition according to embodiment 7.11, wherein the crystalline form of the compound of formula (1) is Form A as defined in any one of embodiments 1.1 to 1.17.

[0124] Pharmaceutical compositions containing a crystalline form of the compound of formula (1) as defined in any one of embodiments 1.0 to 5.2 (e.g., as defined in any one of embodiments 7.1 to 7.12) can be formulated according to known techniques, see, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, USA.

[0125] Thus, the tablet composition (as in embodiment 7.9) can contain a unit dose of active compound together with an inert diluent or carrier such as a sugar or sugar alcohol, e.g., lactose, sucrose, sorbitol or mannitol; and / or a non-sugar derived diluent such as sodium carbonate, calcium phosphate, talc, calcium carbonate, or a cellulose or its derivatives such as methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, and starch such as corn starch. Tablets can also contain standard ingredients such as binders and granulating agents such as polyvinylpyrrolidone, disintegrants (e.g., swellable cross-linked polymers such as cross-linked carboxymethylcellulose), lubricants (e.g., stearates), preservatives (e.g., parabens), antioxidants (e.g., BHT), buffers (e.g., phosphate or citrate buffers), and effervescent agents such as citrate / bicarbonate mixtures. Such excipients are well known and need not be discussed in detail here.

[0126] Capsule formulations (as in embodiment 7.9) may be of the hard or soft gelatin variety and may contain the active ingredient in solid, semi-solid or liquid form. Gelatin capsules may be formed from animal gelatin or its synthetic or vegetable derived equivalents.

[0127] Solid dosage forms (e.g. tablets, capsules, etc.) may be coated or uncoated, but typically have a coating, such as a protective film coating (e.g. wax or varnish) or a release-controlling coating. Coatings (e.g. Eudragit™-type polymers) can be designed to release the active ingredient at a desired location in the digestive tract. Thus, coatings can be selected to degrade under specific pH conditions in the digestive tract, thereby selectively releasing the compound in the stomach or ileum or duodenum.

[0128] Instead of, or in addition to, a coating, the drug can be presented in a solid matrix that includes a release controlling agent, such as a release retarding agent that can be adapted to selectively release the compound under conditions of varying acidity or alkalinity within the gastrointestinal tract. Alternatively, the matrix material or release retarding coating can take the form of an erodible polymer (e.g., a maleic anhydride polymer) that is substantially continuously eroded as the dosage form passes through the gastrointestinal tract.

[0129] Compositions for topical use include ointments, creams, sprays, patches, gels, drops and inserts (e.g., intraocular inserts). Such compositions can be formulated according to known methods.

[0130] Compositions for parenteral administration (as in embodiments 7.11-7.12) are typically presented as sterile fine aqueous or oily suspensions, or may be provided in finely divided sterile powder form for extemporaneous reconstitution with sterile water for injection.

[0131] Examples of formulations for rectal or vaginal administration include pessaries and suppositories which may be formed, for example, from a shaped moldable or waxy material containing the active compound.

[0132] The composition for administration by inhalation can take the form of inhalable powder composition or powder spray, and can be administered in standard form using powder inhalation device or aerosol delivery device. Such devices are well known. For administration by inhalation, powder formulations typically contain active compound together with an inert solid powder diluent such as lactose.

[0133] The crystalline forms of the compound of formula (1) as defined in any one of embodiments 1.0-5.2 are generally presented in unit dosage form and therefore typically contain sufficient compound to provide a desired level of biological activity. For example, according to any one of embodiments 7.7-7.10), a composition intended for oral administration may contain from 2 milligrams to 200 milligrams, more usually from 10 milligrams to 100 milligrams, e.g., 12.5 milligrams, 25 milligrams and 50 milligrams of active ingredient.

[0134] Treatment method It is contemplated that the crystalline forms of the compound of formula (1) as defined in any one of embodiments 1.0 to 5.2 are useful in the prevention or treatment of inflammatory diseases or conditions, immunological diseases or conditions, allergic diseases or disorders, transplant rejection and graft-versus-host disease. Examples of such diseases and conditions are provided above.

[0135] The crystalline form of the compound of formula (1) is typically administered in an amount that is therapeutically or prophylactically useful and generally non-toxic.However, in certain situations (e.g., in the case of life-threatening diseases), the benefits of administering the crystalline form of the compound of formula (1) may outweigh the disadvantages of any toxic effects or side effects, and in such cases it may be considered desirable to administer the compound in an amount that is associated with some degree of toxicity.

[0136] Crystalline forms of the compounds of formula (1) may be administered over an extended period of time to maintain the beneficial therapeutic effect, or may be administered for only a short period of time, or they may be administered in pulsed or continuous doses.

[0137] The crystalline forms of the compound of formula (1) as defined in any one of embodiments 1.0 to 5.2 are generally administered to a subject in need of such administration, such as a human patient.

[0138] A typical daily dose of a crystalline form of the compound of formula (1) may range from up to 1000 mg per day, for example 0.01 milligrams to 10 milligrams per kilogram of body weight, more usually 0.025 milligrams to 5 milligrams per kilogram of body weight, for example up to 3 milligrams per kilogram of body weight, more typically 0.15 milligrams to 5 milligrams per kilogram of body weight, although higher or lower doses may be administered if necessary.

[0139] As an example, an initial starting dose of 12.5 mg may be administered 2-3 times per day. The dosage may be increased by 12.5 mg per day every 3-5 days until the maximum tolerated and effective dose for the individual is reached, as determined by the physician. Ultimately, the amount of compound administered will be commensurate with the nature of the disease or physiological condition being treated, and the therapeutic benefits and presence or absence of side effects provided by a given dosing regimen, and will be at the discretion of the physician.

[0140] The crystalline forms of the compound of formula (1) may be administered as the sole therapeutic agent or may be administered in combination therapy with one or more other compounds, such as steroids, interferons, apremilast (for psoriasis) or methotrexate (for rheumatoid arthritis).

[0141] Diagnostic methods Prior to administration of the compounds of the invention, patients may be screened to determine whether the disease or condition with which the patient is suffering or may be suffering is susceptible to treatment with a compound having activity against TYK2.

[0142] Thus, in further embodiments (8.1 to 8.3), the present invention provides: 8.1 A crystalline form of the compound of formula (1) as defined in any one of embodiments 1.0 to 5.2 for use in the treatment or prevention of a disease state or condition in a patient who has been screened and determined to be suffering from, or at risk of suffering from, a disease or condition that is susceptible to treatment with a compound having activity against TYK2 kinase. 8.2 Use of a crystalline form of the compound of formula (1) as defined in any one of embodiments 1.0 to 5.2 for the manufacture of a medicament for treating or preventing a disease state or condition in a patient who has been screened and determined to be suffering from or at risk of suffering from a disease or condition that is susceptible to treatment with a compound having activity against TYK2 kinase. 8.3 A method for the diagnosis and treatment of a disease state or condition mediated by TYK2 kinase, comprising: (i) screening a patient to determine whether the disease or condition from which the patient is suffering or likely to be suffering is one that is susceptible to treatment with a compound having activity against the kinase; and (ii) if the patient is shown to have such a susceptible disease or condition, then administering to the patient an effective TYK2 inhibitory amount of a crystalline form of the compound of Formula (1) as defined in any one of embodiments 1.0 to 5.2.

[0143] A subject (e.g., a patient) may be subjected to a diagnostic test to detect a marker indicative of the presence of, or a susceptibility to, a disease or condition in which TYK2 is involved. For example, a subject may be screened for genetic markers indicative of a susceptibility to developing an autoimmune or inflammatory disease.

[0144] The genetic marker may include a particular allele or single nucleotide polymorphism in the TYK2 gene that is indicative of susceptibility to an autoimmune disease such as multiple sclerosis (see, e.g., Ban et al., European Journal of Human Genetics (2009), 17, 1309-1313) or an inflammatory bowel disease such as Crohn's disease (see, e.g., Sato et al., J. Clin. Immunol. (2009), 29:815-825). The genetic marker may be, for example, a single nucleotide polymorphism in the TYK2 gene, or may be a haplotype that includes a single nucleotide polymorphism in the TYK2 gene and a polymorphism in another gene.

[0145] Diagnostic tests are typically performed on a biological sample selected from a blood sample, a biopsy sample, a stool biopsy, sputum, chromosome analysis, pleural effusion, peritoneal fluid, or urine.

[0146] Methods for identifying genetic markers, such as single nucleotide polymorphisms, are well known. Examples of suitable methods for identifying such markers are described in Ban et al. and Sato et al., supra. [Brief description of the drawings]

[0147] [Figure 1] 1 shows the XRPD pattern of amorphous (2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)-anilino]oxazole-4-carboxamide. The top trace is of the amorphous compound formed after drying under vacuum at 45° C. for 1 hour, and the bottom trace is of the amorphous compound that was further dried under vacuum at 45° C. for about 19 hours and 15 minutes. [Diagram 2] Figure 2 is an overlay of DSC and TGA thermographs of the amorphous compound after initial drying under vacuum at 45°C for 1 hour, followed by further drying under vacuum at 45°C for about an additional 19 hours and 15 minutes. The top line is the TGA thermograph and the bottom line containing the peak is the DSC thermograph. [Diagram 3] FIG. 3 shows the XRPD pattern of crystalline form A. [Figure 4] Figure 4 is an overlay of the DSC and TGA thermographs of crystalline form A. The top trace is the TGA thermograph and the bottom trace containing the peak is the DSC thermograph. [Diagram 5] FIG. 5 is a DVS isotherm profile of crystalline form A. [Figure 6] FIG. 6 shows the XRPD pattern of crystalline form B. [Figure 7] FIG. 7 shows the DSC thermograms of three samples of crystalline form B, represented by lines B-1, B-2 and B-3. [Figure 8] FIG. 8 is a DVS isotherm profile of crystalline form B. [Figure 9] FIG. 9 shows the XRPD pattern of crystalline form C. [Figure 10] FIG. 10 shows a comparison of DSC thermograms between crystalline form A (line A), crystalline form B (line B) and crystalline form C (line C). [Figure 11] FIG. 11 shows the XRPD pattern of crystalline form D. [Figure 12] FIG. 12 shows the DSC thermogram of crystalline form D. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0148] example The invention will now be illustrated, but not limited, by reference to specific embodiments described in the following examples.

[0149] Abbreviation In the examples below, the following abbreviations are used: [Table 13]

[0150] Analysis conditions NMR spectra were recorded on a Bruker 400 MHz instrument or a JEOL ECX 400 MHz spectrometer equipped with an autosampler. In Example 1, NMR spectra were recorded on a Bruker instrument unless otherwise indicated.

[0151] HPLC separation was performed using a Phenomenex LUNA-C18(2) 5μ particle size, 2×50 mm column.

[0152] X-ray Powder Diffraction (XRPD) Powder X-ray diffraction patterns were collected on a PANalytical diffractometer using Cu Kα radiation (45 kV, 40 mA), a θ-θ goniometer, a focusing mirror, divergence slits (½ inch), Soller slits (4 mm) in both the incident and diverging beams, and a PIXcel detector. The software used for data collection was X'Pert Data Collector, version 2.2f, and data were presented using X'Pert Data Viewer, version 1.2d. XRPD patterns were acquired under ambient conditions with a transparent foil sample stage (polyimide-Kapton, 12.7 μm thick film) under ambient conditions using a PANalytical X'Pert PRO. The data collection range was 2.994-35° 2θ, and the continuous scan speed was 0.202004° / s.

[0153] Differential Scanning Calorimetry (DSC) DSC data were collected on a PerkinElmer Pyris 6000 DSC equipped with a 45-position sample holder. The instrument was verified for energy and temperature calibration using certified indium. A predetermined amount of sample, 0.5-3.0 mg, was placed in an aluminum pan with a pinhole and heated at 20 °C / min from 30 °C to 350 °C or varied as indicated by the experiment. A purge of dry nitrogen at 20 ml / min was maintained over the sample. Instrument control, data acquisition and analysis were performed using Pyris Software v11.1.1 revision H.

[0154] Thermogravimetric analysis (TGA) TGA data were collected on a PerkinElmer Pyris 1 TGA equipped with a 20-position autosampler. The instrument was calibrated for certified weight and temperature using certified Alumel and Perkalloy. A predetermined amount of sample, 1-5 mg, was loaded into a pre-tared aluminum crucible and heated from ambient to 400°C at 20°C / min. A nitrogen purge at 20 ml / min was maintained over the sample. Instrument control, data acquisition and analysis were performed using Pyris Software v11.1.1 revision H.

[0155] optical microscopy Optical microscopy was performed using a Leica DME polarizing microscope and an Infinity 1 digital video camera for image capture. A small amount of each sample was placed on a glass slide and dispersed as much as possible. Samples were observed at appropriate magnification and various images were recorded. Image scale bars were calibrated to an outer reticle of 0.1 mm / 0.002 mm DIV.

[0156] Hot Stage Microscopy (HSM) Hot stage microscopy was performed using a Leica DME polarizing microscope coupled with a Mettler-Toledo MTFP82HT hot stage and a digital video camera for image capture. A small amount of each sample was mounted on a glass slide, isolating individual particles as much as possible. Samples were viewed at appropriate magnification and partial polarized light while being heated from ambient temperature, typically at 20°C / min, unless an alternative heating rate is specified.

[0157] Dynamic Vapor Sorption Sorption isotherms were obtained using a Hiden Isochema moisture sorption analyzer (model IGAsorp) controlled by IGAsorp Systems Software V6.50.48. The samples were maintained at a constant temperature (25°C) by the instrument controls. Humidity was controlled by mixing dry and wet nitrogen flows, with a total flow rate of 250 ml / min. The instrument was verified for relative humidity content by measuring three calibrated Rotronic salt solutions (10-50-88%). The weight change of the sample was monitored as a function of humidity by a microbalance (accuracy + / - 0.005 mg). A defined amount of sample was placed in a tared mesh stainless steel basket under ambient conditions. A complete experimental cycle typically consisted of three scans (sorption, desorption and sorption) at constant temperature (25°C) and 10% RH intervals over the range 0-90% (60 min for each humidity level). This type of experiment should demonstrate the ability of the test sample to absorb (or not absorb) moisture over a set of well-defined humidity ranges.

[0158] Karl Fischer titration The water content in the samples was determined using a Mettler Toledo Volumetric Karl Fischer Titrator. The titrant was HIDRANAL composite 5 and the solvent was HIDRANAL Methanol dry. Approximately 0.2 g of sample mass was charged and mixed for 600 seconds.

[0159] Mya4 reaction station Equilibrations or crystallizations requiring temperature control and / or defined heating / cooling profiles are performed on a Radley Mya4 Reaction Station, a 4-zone reaction station with magnetic and overhead stirring capabilities and a temperature range of -30 to 180°C for 2-400ml scale mixtures. Required reaction conditions are programmed via the Mya 4 Control Pad. Temperature control is verified in-house biannually.

[0160] Example 1 2-(2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)anilino]-oxazole-4-carboxamide [ka] 1A. Preparation of 5-amino-2-(2,6-dichlorophenyl)-oxazole-4-carbonitrile [ka] 2,6-Dichlorobenzoyl chloride (10 g, 47.74 mmol) was slowly added to a solution of aminomalononitrile p-toluenesulfonate (13.3 g, 52.51 mmol) in NMP (50 mL). The reaction mixture was heated at 110° C. for 14 h, then quenched with water (100 mL) and the resulting solid was collected by filtration. The crude product was dissolved in ethyl acetate (100 mL), washed with water (40 mL×2), and the organic layer was dried over Na2SO4. The solvent was removed to give the title compound (19 g, crude) as a white solid. 1 H NMR (400MHz, CDCl3): δ:7.37-7.35(m,2H),7.29-7.26(m,1H),6.19(s,2H).

[0161] 1B. Preparation of 5-bromo-2-(2,6-dichlorophenyl)-oxazole-4-carbonitrile [ka] To a solution of 5-amino-4-cyano-2-(2,6-dichlorophenyl)-oxazole (9.0 g, 35.42 mmol) in CH2Br2 (50 mL) was added bromo(trimethyl)silane (13.56 g, 88.55 mmol). Then tert-BuONO (36.53 g, 354.20 mmol) was added very slowly at 0 °C under a protective N2 atmosphere, and the mixture was stirred at 0 °C for 2.5 h. The reaction mixture was then concentrated under reduced pressure to remove CH2Br2, water (H2O 100 mL) was added, and the resulting mixture was extracted with DCM (100 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue, which was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 50 / 1 to 10:1). The title compound (8 g, 71.03% yield) was obtained as a white solid.

[0162] 1B(a). Alternative Preparation of 5-Bromo-2-(2,6-dichlorophenyl)-oxazole-4-carbonitrile MeCN (7.5 L) was added to CuBr2 (880 g, 3.94 mol) in a flask at room temperature under N2, and the resulting mixture was cooled to 0-4 °C. tBuONO (90% active, 475 mL, 5.68 mol) was added, followed by a solution of 5-amino-4-cyano-2-(2,6-dichlorophenyl)-oxazole (500 g, 1.97 mol) in MeCN (2.5 L) at 0-4 °C. The reaction mixture was stirred at 5 °C for 30 min and then warmed to 10 °C over 1 h, after which LC showed the reaction was complete. The reaction mixture was divided into two equal portions (ca. 5.5 L) for workup. The first portion was quenched with 1 M HCl(aq) (7.5 L) [exotherm 20-27 °C] and extracted with EtOAc (2 x 6.0 L). The extraction procedure was repeated with a second portion, and the organic phases were combined (ca. 24 L), dried over MgSO4, reduced under reduced pressure, and then azeotroped with IPA (4.8 L) to give 711 g of crude material. The crude material was slurried in IPA (0.63 L) under N2 at room temperature for 2 h, filtered, washed (cold IPA, 2 x 0.1 L), and the resulting pale yellow solid was dried under reduced pressure at 40°C for 18 h to give 390 g (62% yield) at 87% by LC.

[0163] 1C. Preparation of 4-(4-nitrobenzoyl)-1,1-dioxo-1,4-thiazinane [ka] To a mixture of 4-nitrobenzoic acid (5 g, 29.92 mmol) and 1,4-thiazinane 1,1-dioxide hydrochloride (5.1 g, 29.92 mmol) in DMF (50 mL) was added HOBt (6.1 g, 44.88 mmol), EDCI (8.6 g, 44.88 mmol), Et3N (6.1 g, 59.84 mmol) in one portion at 15 °C under N2. The mixture was stirred at 15 °C for 14 h. The reaction mixture was diluted with saturated Na2CO3 (300 mL) and extracted with EtOAc (150 mL x 3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give the title compound (6.5 g, crude) as a white solid. 1 H NMR (400 MHz, CDCl3): δ:8.27(d,J=8.8 Hz,2H),7.55(d,J=8.8 Hz,2H),4.33-3.75(m,4H),3.22-2.75(m,4H).

[0164] 1D. Preparation of 4-(4-aminobenzoyl)-1,1-dioxo-1,4-thiazinane [ka] To a solution of 4-(4-nitrobenzoyl)-1,1-dioxo-1,4-thiazinane (5.5 g, 19.35 mmol) in MeOH (100 mL) was added Pd / C (1.0 g, 19.35 mmol) under N2. The suspension was degassed under reduced pressure and purged with H2 several times, then stirred under H2 (15 psi) at 15 °C for 14 h. The reaction mixture was filtered and the filtrate was concentrated to give the title compound (4.5 g, 91.45% yield) as a white solid. 1H NMR(400MHz,(CDCl3):δ:7.36-7.26(m,2H),6.80-6.61(m,2H),4.26-4.08(m,4H),4.06-3.88(m,2H),3.21-2.95(m,4H)

[0165] 1E. Preparation of 2-(2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)anilino]oxazole-4-carbonitrile [ka] 1,4-Dioxane (13 mL) was added to a mixture of 5-bromo-4-cyano-2-(2,6-dichlorophenyl)-oxazole (500 mg, 1.57 mmol), 4-(4-aminobenzoyl)-1,1-dioxo-1,4-thiazinane (399.25 mg, 1.57 mmol) and Pd(dba)2 (90.28 mg, 157 μmol), DPPF (130.56 mg, 235.5 μmol), K2CO3 (976.45 mg, 7.07 mmol) in a sealed reaction tube and subjected to microwave heating at 120° C. for 4 h. The resulting reaction mixture was filtered, concentrated under reduced pressure, and water (30 mL) was added followed by extraction with DCM (50 mL×3). The combined organic phase was dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue, which was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=10 / 1-2 / 3) to give the title compound (110 mg, 14.26% yield) as a brown solid.

[0166] 1F. Preparation of 2-(2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)anilino]oxazole-4-carboxamide [ka] A mixture of (2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)anilino]oxazole-4-carbonitrile (100 mg, 203.52 μmol) in H2SO4 (1 mL) at 0° C. was stirred at 15° C. for 2 h under a N2 atmosphere. LCMS analysis after this time showed the reaction to be complete, so the reaction mixture was quenched with ice at 0° C. and then filtered. The filtrate was extracted with EtOAc (30 mL: 10 mL×3) and the combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue that was purified by preparative HPLC (TFA conditions). The title compound, 2-(2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)-anilino]oxazole-4-carboxamide (25 mg, 24% yield, 99.61% purity) was obtained as a yellow solid. 1 H NMR(400MHz,(CDCl3):δ:9.05(s,1H),7.50-7.48(m,2H),7.46-7.44(m,3H ),7.41-7.38(m,2H),6.50(s,1H),5.38(s,1H),4.12(s,4H),3.07(s,4H). MS(ESI):mass calc'd.for C 21 H 18 Cl2N4O5S 508.0408.04,m / z found,509.0 [M+H]+.

[0167] 1G. Preparation of amorphous 2-(2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)anilino]oxazole-4-carboxamide 2-(2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)-anilino]oxazole-4-carboxamide is purified by HPLC, after which the solvent is rapidly evaporated (e.g., by rotary evaporation) from the eluent containing the compound to obtain an amorphous form of the compound.

[0168] A larger scale preparation of the amorphous compound was performed by dissolving 2-(2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)-anilino]oxazole-4-carboxamide (1.436 g) in 20 volumes of THF and swirling the mixture at 25° C. to form a solution within 15 minutes. The solution was clarified (0.45 μm nylon filter) to give a clear yellow solution with a dark residue remaining on the filter surface. The solution was reduced to a yellow foamy solid within 2 minutes at 40° C. under reduced pressure and dried for an additional hour at 45° C. under reduced pressure on a rotary evaporator.

[0169] A portion of the solid was sampled (batch 1) and the bulk (batch 2) was dried under vacuum at 45° C. for approximately 19 hours and 15 minutes to yield 1.15 g of a yellow brittle solid from the vessel.

[0170] XRPD examination (Figure 1) revealed that both the wet lot (Batch 1) and the dry lot (Batch 2) were amorphous.

[0171] Thermal examination of Batch 2 (Figure 2) revealed evidence of small endotherms in the DSC thermograph at approximately 92°C and 111°C leading to a significant exotherm with onset and peak minima at approximately 162°C and 188°C, respectively. The TGA thermograph showed a clear initial mass loss of 1.052 wt% from approximately 25-70°C and a broader mass loss of 4.851 wt% from approximately 78-160°C, leading to a third broad mass loss of 5.787 wt% from approximately 160-240°C prior to the onset of decomposition.

[0172] Examination of Batch 2 by Hot Stage Microscopy (HSM) revealed particle migration and solid shrinkage from about 83°C, with onset of melting by about 102°C and completion of melting by about 145°C, with no evidence of crystallization from the melt. Increased discoloration in the melt was evident by about 175°C.

[0173] Batch 1 1H NMR spectroscopy (Jeol) revealed residual THF and DMSO contents of 7.19 and 0.50 wt %, respectively. 1 H NMR spectroscopy revealed slightly reduced residual THF and DMSO contents of 4.90 and 0.36 wt %, respectively. The stoichiometric THF solvate requires the presence of approximately 12.4 wt % THF.

[0174] The total solvent content (and potentially residual water) corresponds to the first two mass loss steps from 25-70°C and 78-160°C in the TGA thermograph, while the remaining mass loss is believed to be due to decomposition in the melt.

[0175] Example 2 Conversion of amorphous 2-(2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)anilino]oxazole-4-carboxamide to a crystalline form Amorphous compound (batch 2), 24x approximately 40±2 mg, was weighed into 24 crystallization tubes. 5 volumes of selected solvent were charged to the solid at 25°C and observations were made. A significant number of mixtures showed dissolution upon solvent addition followed by a suspension within 10-15 minutes, which was believed to be the result of residual THF content and / or potentially indicating morphology change and crystallization. If a suspension remained, an additional 5 volumes of solvent were charged (10 volumes total) and observations were made. The mixture was heated to 50°C (38°C for DCM) and observations were recorded immediately. The mixture was allowed to equilibrate at temperature for approximately 17 hours and observations were recorded. The mixture was cooled to 25°C over approximately 2 hours 15 minutes and equilibrated for approximately 4 1 / 2 hours and observations were recorded. The mixture was heated to temperature and equilibrated for approximately 16 hours and observations were recorded. The mixture was cooled to 25°C over approximately 2 hours 15 minutes and equilibrated for approximately 1 hour and observations were recorded and the solid was isolated.

[0176] Once isolated, all solids were dried under air under reduced pressure for approximately 10-20 minutes and then dried at 45° C. under vacuum for 68 hours.

[0177] Observations during solvent addition and thermal conditioning are summarized in Table 1. Crystal morphologies obtained from different conditions are summarized in Table 2. [Table 14]

[0178] In Table 1: *1 Fill with up to 10 volumes of additional solvent Susp. = Suspension Haze = Mostly dissolved YS = Yellow solid precipitate above mixture level [Table 15]

[0179] Of the 24 solvents / solvent mixtures evaluated, the amorphous compound showed complete / significant dissolution upon the addition of 5 volumes of solvent in 15 of the mixtures. However, within 10-15 min, 12 of these mixtures produced suspensions. After prolonged equilibration at 50 °C, suspensions were obtained from all mixtures.

[0180] The predominant XRPD pattern of the dried solid was Form B (14 hits).

[0181] Form A was isolated exclusively from the aqueous solvent mixture.

[0182] Form C was isolated from nitromethane, DCM, EtOH and MeCN.

[0183] Equilibration in anisole afforded a new form, arbitrarily designated form E.

[0184] Form E 1 H NMR spectroscopy (Jeol) showed residual anisole, THF and DMSO contents to be 1.14, 0.86 and 0.52 wt %, respectively (17.5 wt % anisole was required for the 1:1 solvate).

[0185] Thermal examination of Form E revealed two endotherms peaking at 187° C. and 226° C., not significantly different from the main endotherms of Forms A and B, respectively.

[0186] Thermal manipulation of Form E by heating it to 200° C. beyond the first endotherm and then cooling showed the removal of the first endotherm upon reheating. Not enough solid remained for XRPD examination of the thermally manipulated material.

[0187] HSM of form E revealed particle excitation at 170 °C, resulting in shrinkage from 179 °C and melt by 192 °C. Stepwise crystallization was observed in the melt from 192 °C until crystals melted at 224–230 °C.

[0188] Equilibration of the amorphous compound in EtOAc afforded a new form, designated Form D.

[0189] Form D 1 H NMR spectroscopy indicated residual EtOAc and DMSO contents of 4.30 and 0.15 wt %, respectively (1:1 solvate requires 14.7 wt % EtOAc). No detectable THF was observed.

[0190] Thermal examination of Form D (see FIG. 12) revealed a complex DSC thermogram with a broad endotherm-exotherm peaking at 171° C. and 179° C., respectively (the endotherms similar to Form C), followed by two sharper endotherms peaking at 209° C. and 229° C. (the latter similar to Form B).

[0191] Thermal manipulation by heating the solid to 180° C. above the endotherm-exotherm and then cooling showed elimination of the endotherm-exotherm event on reheat. Heating the solid to 215° C. above the second endotherm and then cooling and reheating showed a slight endotherm at about 145° C. but no other events until the endotherm of Form B. Not enough solid remained for XRPD examination of the thermally manipulated material.

[0192] HSM of Form D revealed particle excitation at 162 °C resulting in shrinkage from 168 °C and melt by 182 °C. The solid remained in the melt and potentially crystallized until the crystals melted at 226 °C-231 °C, similar to Form E.

[0193] Example 3 Alternative hydrolysis conditions for the conversion of 2-(2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)anilino]oxazole-4-carbonitrile to 2-(2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)anilino]oxazole-4-carboxamide In step 1F of Example 1, partial hydrolysis of the nitrile to the carboxamide is carried out using sulfuric acid. In the alternative, the partial hydrolysis step can be carried out using a mixture of trifluoroacetic acid (TFA) and sulfuric acid.

[0194] Thus, TFA (1166 mL) was added to 2-(2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)anilino]oxazole-4-carbonitrile (350 g, 7.12 mmol) and the mixture was stirred at room temperature for 30 min and then cooled to 0-10 °C. Concentrated H2SO4 (584 mL) was added to the mixture over 30 min [exothermic process] while maintaining the temperature in the range of 0-20 °C. After the addition of H2SO4 was complete, the reaction mixture was warmed to 15-25 °C and stirred at room temperature for 5 h after which liquid chromatography showed 3% remaining starting material. The reaction was quenched by addition to a mixture of concentrated NH3 (3.0 L) and ice (4.0 Kg) over 30 min while maintaining the temperature below 25 °C [exothermic] [pH was shown to be >10 after addition]. The resulting slurry was stirred for 15 minutes, then filtered, washed (H2O, 1.0 L) and sucked dry. The wet filter cake was reslurried in water (3.5 L) for 3 hours, refiltered, washed (H2O, 1.8 L) and dried overnight at 50° C. under vacuum to give (2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)anilino]-oxazole-4-carboxamide (402 g) in 93.2% purity with a residual starting material level of 0.97% (by LC). The partially purified material was slurried in MeCN (1.5 L) for 1 hour at room temperature, filtered, washed (MeCN 0.5 L) and dried overnight at 50° C. under vacuum to give 195 g of product. The product was further purified by dissolving in DMSO (500 mL) at room temperature, polishing filtered, washing (DMSO, 80 mL), and then adding to HO (3.8 L) over 2 hours while maintaining the temperature below 25° C. The resulting slurry was stirred for 30 minutes, then filtered, washed (HO, 2×900 mL), and dried under reduced pressure at 50° C. to give 170.8 g (44% yield) of (2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)anilino]oxazole-4-carboxamide. 1The activity was 95% by H NMR assay and purity was 97.1% by LC, with 2.3% HO by KF. The MeCN solution (80.9% by LC) was further reprocessed using column chromatography to obtain 93.9% by LC and 94.2% by HCl. 1 61.1 g of product was obtained with 79% activity by 1 H NMR assay.

[0195] The aqueous workup used in this method for preparing 2-(2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)anilino]oxazole-4-carboxamide affords crystalline form A of the compound.

[0196] Characterization data for crystal forms A, B, C and D Form A The XRPD pattern of crystalline form A is shown in FIG.

[0197] The XRPD pattern dataset for Form A is shown in Table 3 below. [Table 16]

[0198] Thermal testing (Figure 4) revealed distinct endotherms in the DSC thermograph with onset and maximum at 181.72°C and 193.65°C, respectively. The main endotherm was preceded by a broad endotherm that peaked at approximately 100°C. This broad endotherm corresponded to a mass loss of 2.582 wt% from 30°C to 150°C in the TGA thermograph and was therefore most likely a water loss. A slight weight loss of 0.148 wt% coincided with the main endotherm. The onset of decomposition was observed from approximately 258°C.

[0199] Thermal manipulation by holding at 150 °C for 1 min over the broad endotherm and mass loss revealed a DSC thermogram similar to the input, with little evidence of the broad endotherm shown in Figure 4. The thermal manipulation was thought to anneal the material. The thermal manipulation had no obvious effect on the XPRD diffraction pattern of the solid.

[0200] DVS examination of crystalline form A (Figure 5) revealed a weight loss of about 2.75 wt% upon initial desorption from 50% RH to 0% RH and a total weight gain of about 3.25 wt% upon sorption from 0% RH to 90% RH. Repeated desorption and sorption were similar to the first step with little evidence of hysteresis. Weight change was relatively stable between 20% RH and 90% RH, but increased significantly between 0% RH and 20% RH.

[0201] Form B The XRPD pattern of crystalline form B is shown in FIG.

[0202] The XRPD pattern dataset for Form B is shown in Table 4 below. [Table 17]

[0203] FIG. 7 shows the DSC profiles of three samples of Form B prepared by different methods.

[0204] The DSC profile of a sample of crystalline form B prepared by equilibration of form A in nitromethane is represented by line B-1 in Figure 7. This form is predominantly form B, but was shown by XRPD (diffractogram not shown) to contain some form A. DSC examination of this crystalline form shows a single endotherm with an onset and maximum at 228°C and 232°C, respectively.

[0205] The DSC profile of a sample of crystalline form B prepared by equilibration in MEK is represented by line B-2 in Figure 7. The DSC thermograph shows endotherms with onset and maximum at 230°C and 233°C, respectively, with a preceding shoulder at 229°C. With the exception of the shoulder, the profile is similar to B-1.

[0206] The DSC profile of a third sample of Form B is shown by line B-3 and is characterized by an endotherm with an onset and maximum at a similar temperature as B-1, but with a bimodal peak at 236°C.

[0207] DVS examination of Form B (see FIG. 8) showed a weight loss of about 0.38 wt% upon initial desorption from 50% RH to 0% RH and a total weight gain of about 0.57 wt% upon sorption from 0% RH to 90% RH. Repeated desorption and sorption were similar to the first step, with hysteresis of about 0.11 wt%, most evident between 10% RH and 60% RH. Weight change was relatively stable between 0% RH and 90% RH. XRPD examination of the solids isolated after DVS at 0% RH and 90% RH (diffractograms not shown) showed no clear evidence of morphological change from the input version.

[0208] Form C The XRPD pattern of crystalline form C is shown in FIG.

[0209] The XRPD pattern dataset for Form C is shown in Table 5 below. [Table 18]

[0210] FIG. 10 shows a comparison of the DSC profiles of Forms A, B and C, represented by lines A, B and C, respectively.

[0211] Form C used in this DSC study was prepared by equilibration in THF at 25° C. using Form A as the starting material.

[0212] The profile of Form C is characterized by a broad endotherm from 140°C to 180°C, with a peak maximum at 173°C, followed by an endotherm similar to Form B with an onset at 224°C and a maximum at 232°C.

[0213] HSM of Form C revealed particle eruptions from about 147° C., resulting in partial melting by 187° C. Slight crystallization was observed in the melt up to about 210° C. Shrinkage was observed from about 220° C., with melting complete by 237° C.

[0214] A sample of Form C was thermally manipulated by holding at 180° C. on the TGA. This revealed mass losses of 0.42 and 2.08 wt % from 25 to 68° C. and 86 to 185° C. DSC evaluation of the manipulated material revealed thermograms characteristic of Form B. XRPD examination (diffractograms not shown) revealed a morphological transformation from Form C to Form B.

[0215] Form D The XRPD pattern of crystalline form D is shown in FIG.

[0216] The XRPD pattern dataset for Form D is shown in Table 6 below. [Table 19]

[0217] Figure 12 shows the DSC thermogram of Form D. Form D was prepared by equilibration of the amorphous compound in ethyl acetate at 25°C.

[0218] Form D 1 1 H NMR spectroscopy (JEOL-spectrum not shown) indicated residual EtOAc and DMSO contents of 4.30 and 0.15 wt %, respectively (1:1 solvate requires 14.7 wt % EtOAc).

[0219] Thermal examination (Figure 12) revealed a complex DSC thermogram with a broad endotherm-exotherm peaking at 171°C and 179°C, respectively (the endotherms similar to Form C), followed by two sharper endotherms peaking at 209°C and 229°C (the latter similar to Form B).

[0220] Thermal manipulation by heating the solid to 180° C. above the endotherm-exotherm and then cooling (DSC trace not shown) showed elimination of the endotherm-exotherm event on reheat. Heating the solid to 215° C. above the second endotherm and then cooling and reheating showed a slight endotherm at about 145° C., but no other events until the endotherm of Form B. Not enough solid remained for XRPD examination of the thermally manipulated material.

[0221] HSM revealed particle excitation at 162 °C, resulting in contraction from 168 °C and melting by 182 °C. Solids remained in the melt, potentially crystallizing, until the crystals melted at 226 °C-231 °C.

[0222] Example 4 Conversion of Form A of 2-(2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)anilino]oxazole-4-carboxamide to other crystalline forms Equilibration of Form A in a variety of solvents leads to very different outcomes than equilibration of the amorphous compound in the same range of solvents.

[0223] Samples of crystalline form A, 24 x approximately 50 ± 2 mg, were weighed into 24 crystallization tubes. 0.25 ml, 5 volumes of the selected 24 solvent were charged to the solid at 25°C and observations were made. If a suspension remained, an additional 0.25 ml, 5 volumes of solvent was charged to a total of 1 ml (20 volumes) and equilibrated for approximately 30 minutes between each solvent charge. The mixture was heated to 50°C (38°C for DCM) and observations were recorded immediately. The mixture was equilibrated at temperature for approximately 21 hours and observations were recorded. The mixture was cooled to 25°C over approximately 2 1 / 2 hours and equilibrated for approximately 4 hours and observations were recorded. The mixture was heated to temperature and equilibrated for approximately 16 1 / 2 hours. Observations were recorded and if a suspension remained a sample was taken. The mixture was cooled to 25°C over approximately 1 1 / 2 hours and equilibrated for approximately 1 hour and observations were recorded and the solid was isolated.

[0224] Once isolated, all solids were dried under air under reduced pressure for approximately 10-20 minutes and then dried under reduced pressure at 45° C. for approximately 17 hours. Once isolated at 25° C., the filtrate was retained for compound solubility as determined by HPLC.

[0225] Observations during solvent addition and thermal conditioning are summarized in Table 7. The form fate, solubility and overall CP (at 25° C.) by XRPD at temperature and 25° C. of the solids are summarized in Table 8.

[0226] Of the 24 solvents / solvent mixtures evaluated, the compound remained in suspension upon addition of 21 solvents. Of the three solvents in which complete / partial dissolution occurred, CPME and THF produced suspensions after extended equilibration at 50° C., and only THF / water, 4:1, remained in solution, with no solids able to be recovered from 15 volumes.

[0227] Moderate compound solubility (1-10 mg / ml) was observed in half of the solvents, with low compound solubility (<1 mg / ml) observed in cyclohexane, 2-chlorobutane, heptane, TBME, and water. Significant compound solubility (>10 mg / ml) was observed in anisole, nitromethane, THF, DCM, and THF / water, 4:1.

[0228] The predominant XRPD pattern of the dried solid was Form A, the input version.

[0229] Form B was obtained by equilibration in MEK.

[0230] Nitromethane recovered primarily Form B with very little evidence of Form A. Equilibration in EtOAc and MeCN recovered a mixed version of Forms A / B.

[0231] The crystal forms produced by equilibration in THF and DCM were found to be temperature dependent: use of THF as the equilibration solvent at 50° C. afforded form B, whereas cooling to 25° C. afforded form C. Conversely, DCM at 38° C. afforded form C, whereas cooling to 25° C. afforded form B. [Table 20] [Table 21]

[0232] Example 5 Conversion of Form A of 2-(2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)anilino]oxazole-4-carboxamide to other crystalline forms by dissolution / antisolvent method Equilibration of Form A in a series of solvents with thermal conditioning revealed a range of suitable solvents and anti-solvents. As a result, Form A was dissolved in a series of four solvents at elevated temperatures, clarified, and anti-solvents were added at elevated temperatures to assess the compound's propensity for anti-solvent driven crystallization.

[0233] Form A of 2-(2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)anilino]oxazole-4-carboxamide, 4 x 150-152 mg, was weighed into four crystallization tubes. Four different solvents (see Table 8) were then added to the solid and the resulting mixtures were heated to 60 °C. If suspension persisted, additional solvent was added to achieve dissolution. Once the four mixtures were dissolved, the solutions were clarified and aliquots containing approximately 30 mg of compound were filled into the four crystallization tubes.

[0234] To each of the four aliquots, approximately 5 volumes of antisolvent (see Table 8) was added at 60° C. and observations were made immediately. After equilibration and observation for 1 hour, an additional 5 volumes of antisolvent was added to all mixtures. If a suspension or immiscible mixture had formed, no additional antisolvent was added. All solutions and hazes had additional antisolvent added up to a total charge of 20 volumes.

[0235] The mixture was allowed to equilibrate at 60°C for an additional hour, then cooled to 25°C over approximately 3 hours and allowed to equilibrate for approximately 14.5 hours. It was observed that most of the mixture formed a suspension. Once isolated, all solids were dried under air under reduced pressure for approximately 1 hour, then dried in an oven at 45°C under reduced pressure for 70 hours.

[0236] Observations made during the antisolvent addition and subsequent cooling procedure are summarized in Table 8. [Table 22]

[0237] The forms produced by each of the 16 solvent-antisolvent combinations are shown below in Table 9. Forms were identified by XRPD diffraction patterns. [Table 23]

[0238] Form A was produced from aqueous-based solvent mixtures, while Form B was produced primarily from non-aqueous mixtures, with the exception of the nitromethane / cyclohexane solvent / anti-solvent combination (which produced Form B with evidence of Form C) and nitromethane / 2-chlorobutane (which produced Form C with evidence of Form B).

[0239] Rapidly cooled antisolvent crystallization Using the following method, anti-solvent crystallization was performed by dissolving 2-(2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)anilino]oxazole-4-carboxamide in a solvent with heating, clarifying the solution, and adding cold anti-solvent.

[0240] 2-(2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)anilino]oxazole-4-carboxamide, 4 × 153–155 mg, was weighed into four crystallization tubes, each charged with a different solvent (see Table 10). The mixture was heated to 60 °C to achieve dissolution and then clarified.

[0241] 1.5 ml of each of the three anti-solvents (see Table 10) was filled into four crystallization tubes and cooled to -10°C.

[0242] A clear solution of 2-(2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)anilino]oxazole-4-carboxamide at 60° C. was added to cold anti-solvent in an aliquot containing approximately 50 mg of compound (approximately 30 volumes of anti-solvent) and observations were immediately recorded.

[0243] The resulting mixture was equilibrated at about -10°C for about 22 hours, observations were made, and solids were isolated. All isolated solids were dried under vacuum in air for about 20 minutes and then dried under vacuum at 45°C for 23 1 / 2 hours.

[0244] Observations made during the anti-solvent addition and subsequent cooling procedures are summarized in Table 10. The crystal morphology (as determined by XRPD) resulting from each solvent-anti-solvent combination is shown in Table 11. For comparative purposes, the crystal morphology produced by anti-solvent addition at 60° C. (see Table 10 above) is also included in Table 11. [Table 24] [Table 25]

[0245] Rapidly cooled antisolvent addition followed by equilibration at -10°C for approximately 22 hours resulted in the formation of primarily form B, although in some cases form C or a mixed version of forms B / C and in only one case form A was formed.

[0246] The results demonstrate that the crystalline form of 2-(2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)anilino]oxazole-4-carboxamide resulting from solvent / antisolvent crystallization depends not only on the nature of the solvent but also on the temperature at which the crystallization is carried out.

[0247] Example 5 Conversion of Form A to Form B by equilibration in methyl ethyl ketone (MEK) Crude crystalline Form A, 2.992 g (2.84 g active material) and seeds of crystalline Form B, approximately 3 mg, approximately 0.1 wt %, were weighed into a vessel. MEK, 6 volumes, was charged to the vessel and the mixture was warmed to 50° C. The resulting suspension was equilibrated at this temperature for approximately 19 hours and then cooled to 25° C. over 1.5 hours. The solid was isolated by filtration, followed by washing with MEK, 1 volume, the vessel and the filter. The washed solid was dried under reduced pressure under air for 1 hour and at 45° C. under reduced pressure for 19.5 hours to give 2.639 g of a pale yellow solid (mass recovery 88.2%).

[0248] XRPD examination of the dried compound (diffractogram not shown) revealed the diffraction pattern of Form B.

[0249] Thus, equilibration of crude crystalline Form A in 6 volumes of MEK at 50° C. successfully yielded Form B with 88.2% recovery at 3 g scale, increased active substance content of 97% (from 95%) and improved CP of 98.85% (from 97.14%).

[0250] The purity of crystalline form B can be further improved by first equilibrating the form A starting material in MeCN / water, 4:1, 4 volumes at 50° C., isolating and drying the purified form A, and then equilibrating form A in MEK as described above. In this way, crystalline form B can be obtained with an improved CP of 98.64% and active substance content of 99%.

[0251] Example 6 Comparison of compression stability of crystalline form A and crystalline form B Compression stability tests were performed on samples from two batches of crystalline form A and two batches of crystalline form B. Pairs of samples of form A and form B were compressed at 10×10 4 They were subjected to compression under a force of N to evaluate the effect on their morphological fate and chemical stability.

[0252] Another pair of samples of Form A and Form B were subjected to similar compressive pressures for an extended period of 7 days to evaluate the effect of long-term compressive forces on the form fate and chemical stability.

[0253] XRPD examination of Form A solids isolated after compression showed a diffraction pattern consistent with the input Form A but with reduced diffraction resolution after both approximately 1 and 7 days of compression, possibly due to limited sample or lower order of the solids.

[0254] XRPD examination of form B solids isolated after compression, like form A, showed diffraction patterns consistent with input pattern B but with reduced diffraction resolution after both approximately 1 and 7 days of compression, likely due to limited sample or lower order solids.

[0255] HPLC evaluation of Form A after 7 days of compression revealed significant chemical degradation, however compression for approximately 1 day showed no discernible chemical degradation within experimental error.

[0256] HPLC evaluation of Form B after both approximately 1 day and 7 days of compression revealed, within experimental error, no change in the impurity profile of Form B.

[0257] The results of the tests showed that crystalline Form A was stable to compressive forces for relatively short periods of time, with no discernible chemical decomposition, but a slight decrease in crystallinity by XRPD and DSC after 23 hours. However, compression for 7 days resulted in significant chemical decomposition.

[0258] Crystalline form B, on the other hand, was stable to short and long term compressive forces and showed no discernible chemical decomposition, although it did show a slight decrease in crystallinity by XRPD and DSC.

[0259] Thus, Form B exhibits improved stability to compression over Form A.

[0260] Based on the test results, crystalline form B is believed to be more suitable for solid formulations, especially those prepared by processes that include a compression step (such as tablets).

[0261] On the other hand, Form A may be more suitable for the preparation of formulations that do not involve a compression step.

[0262] Example 7 biological activity (i) TYK2 and JAK kinase inhibition assays The compounds of formula (1) were assayed for their ability to inhibit TYK2 kinase and other JAK kinases. The activity of the compounds was assayed using the compounds of Examples 25 and 29 in WO 2015 / 032423 and WO 2018 / 073438, respectively, Compound A (2-(2-chloro-6-fluoro-phenyl)-5-[4-(morpholine-4-carbonyl)-phenylamino]-oxazole-4-carboxylic acid amide) and Compound B (2-(2,6-dichloro-phenyl)-5-[4-(morpholine-4-carbonyl)-phenylamino]-oxazole-4-carboxylic acid amide): [ka] The activity was compared with that of

[0263] The substrates and kinases used in the assays are identified in Table 12 below.

[0264] Kinase assays were performed at Reaction Biology Corp., Malvern, Pennsylvania, USA, using the general procedure given below: In this assay, ATP concentration was 100 μM and the highest compound concentration was 10 μM.

[0265] Please note that the TYK2 and JAK kinase data in Table 7 on page 61 of WO 2015 / 032423 were generated using assays in which the ATP concentration was 10 μM, however, as noted above, the assays described in the following protocol used an ATP concentration of 100 μM.

[0266] Assay: 1) Prepare the indicated substrate in freshly prepared basal reaction buffer (20 mM Hepes pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg / ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO). 2) Supply the above substrate solution with cofactors (1.5 mM CaCl2, 16 ug / mL calmodulin, 2 mM MnCl2). 3) Add the indicated kinase to the substrate solution and mix gently. 4) Various concentrations of test compound in DMSO are provided to the kinase reaction mixture. 5) 33 Supply P-ATP (final specific activity 0.01 μCi / μL) to the reaction mixture to initiate the reaction. 6) Incubate the kinase reaction at room temperature for 120 minutes. 7) Spot the reaction mixture onto P81 ion exchange filter paper (Whatman No. 3698-915). 8) Unbound phosphate is removed by washing the filters extensively in 0.75% phosphoric acid. 9) Using Typhoon phosphorimagers (GE Healthcare) 33 The P signal was determined using the nonlinear regression function in Prism (Graphpad software) after subtracting the background from the control reactions containing inactive enzyme. 50 value was determined. [Table 26] Substrate: AXLtide=[KKSRGDYMTMQIG] JAK3tide=[Ac-GEEEEYFELVKKKK-NH2] pEY = polyGlu-Tyr [Glu:Tyr (4:1), molecular weight = 5,000-20,000]

[0267] The results are shown in Table 3 below. [Table 27]

[0268] Although all the tested compounds were shown to have good TYK2 inhibitory activity, the data indicate that the compound of formula (1) is more potent and more selective against TYK2 (especially against TYK2 over JAK2 and JAK3) than prior art compounds A and B.

[0269] (ii) Cytochrome P450 Inhibition Assay The susceptibility of compound (1) to potential drug-drug interactions was tested by assaying its ability to inhibit various cytochrome P450 isoforms. Prior art compound B (see Example 7(i) above) was also tested as a comparative example.

[0270] Test compounds prepared and serially diluted in DMSO were incubated at six concentrations (1% DMSO final) with pooled human liver microsomes in the presence of each isoform of probe substrate to determine their effect on the metabolism of the probe substrate. Incubations (in 96-well plates) were carried out in 0.1 M Tris buffer, pH 7.4, at 37° C., and the reaction was initiated by the addition of the cofactor NADPH (1 mM final concentration).

[0271] At the indicated times, reactions were terminated with acetonitrile containing an analytical internal standard, samples were centrifuged, and the supernatant fractions were analyzed for probe substrate metabolites by mass spectrometry (LC-MS / MS). Instrument responses were normalized to the internal standard and compared to appropriate solvent controls to determine the amount of metabolite formed from the probe substrate relative to these "uninhibited" controls.

[0272] Results are reported as percent inhibition and IC 50 Values ​​(concentrations resulting in a 50% reduction in probe metabolite formation) were calculated using a nonlinear sigmoidal dose-response equation (BioBook): % Inhibition = Min + (Max - Min) / (1 + 10^((Log IC 50 -X)*Hill slope) where X = log concentration.

[0273] The CYP450 isoforms examined and their respective probe substrates are shown in Table 14. [Table 28]

[0274] The assay results are shown in Table 15. [Table 29]

[0275] While all the tested compounds show good CYP inhibition profiles, the data show that the compound of formula (1) has a better CYP inhibition profile (i.e., inhibits the tested CYP isoforms to a lesser extent) than comparative compound B, particularly with respect to CYP2C8 and CYP2D6.

[0276] (iii) hERG channel inhibition assay The potential of compounds to inhibit the hERG potassium channel was determined using a stably transfected hERG-HEK cell line on a Sophion Qube automated electrophysiology platform. Assays were performed at room temperature and hERG tail current recordings were made from individual cells using a single-hole QChip.

[0277] The potency of test compounds to inhibit the hERG channel (IC 50 ) was determined from concentration-response curves generated from eight test compound concentrations, with up to four replicates per concentration.

[0278] Compound concentrations were added to test wells in duplicate to ensure complete exchange of external buffer with test compound. In total, compounds were applied to the wells for >7 minutes.

[0279] The results are shown in Table 16 below. [Table 30]

[0280] All three compounds tested exhibit relatively low hERG activity, however the results demonstrate that the compound of formula (1) has an even lower hERG risk compared to the comparative compound B of the prior art.

[0281] (iv) Hepatocyte stability assay Compound (1) and prior art comparative compound B were tested in a hepatocyte stability assay performed using pooled hepatocytes from mice (male CD-1), rats (male Sprague-Dawley), dogs (male Beagle) and humans (mixed sex). Test and control compounds were incubated with hepatocytes at 37° C. Aliquots were removed at six time points over 1 hour. Samples were centrifuged and the supernatant fractions were analyzed for parent compound by mass spectrometry (LC-MS / MS).

[0282] The amount of compound remaining (expressed as %) was determined from the MS response of each sample compared to the MS response in the T=0 sample and used to determine the half-life and intrinsic clearance of the compound.

[0283] The results are shown in Table 17 below. [Table 31]

[0284] While Comparative Compound B exhibits a good half-life in humans (greater than 2 hours), the data in Table 7 demonstrate that Compound (1) has a significantly reduced clearance rate in all four hepatocyte stability assays compared to Comparative Compound B of the prior art, and therefore the half-life (T 1 / 2 ) is longer than the half-life of comparative compound B in all four assays.

[0285] (v) pSTAT3 inhibition Compound (1) and prior art comparative compounds A and B were tested for pSTAT3 inhibition in response to IL-22 stimulation in serum-starved HT29 cells.

[0286] After serum starvation of HT29 cells overnight, the four test compounds were diluted to generate 9-point half-log dose dilutions with a top concentration of 10 μM, and a vehicle control. HT29 cells were incubated with the test compounds for 20 minutes at 37°C. After further incubation of HT29 cells with 10 ng / ml human IL-22 for 15 minutes, the cells were fixed with 4% PFA for 10 minutes and 90% methanol for 30 minutes, and then labeled with phospho-STAT3 Y705 antibody (CST No. 9145). The cells were rinsed three times using 0.5% BSA / PBS solution, and then incubated with Alexa-488 anti-rabbit secondary antibody.

[0287] The mean fluorescence intensity of phospho-STAT3 in single cells was analyzed by flow cytometry using an Intellicyt iQue instrument and FlowJo software. After subtracting background signal and normalizing to DMSO control, IC was calculated using a four-parameter analysis. 50 It was decided.

[0288] The results are shown in Table 18 below. [Table 32]

[0289] Both Comparative Compound B and Compound (1) had IC of less than 100 nM for pSTAT3 inhibition. 50 It was shown that the compound (1) had an IC 50 The value is the IC 50 was significantly lower than the value.

[0290] (vi) Human primary CD4CD45RO+ cell assay The inhibition of IL-17F production and STAT3 phosphorylation by compound (1) and comparative compound B was measured in Th17 cells derived from human peripheral blood CD4CD45RO+ cells.

[0291] Fresh human peripheral blood CD4CD45RO+ cells were purchased commercially (Generon, UK) in three separate vials from three different volunteers for experimental replicates. Cells were grown in T cell medium (Thermo Fisher) containing 10 ng / ml recombinant human IL-1B (R&D Systems), IL-23 (R&D Systems), TGF-B1 (R&D Systems) and 50 ng / ml IL-6 (R&D Systems) with anti-CD3 / CD28 magnetic Dynabeads (Thermo Fisher). These were expanded for 11 days to induce the expansion of Th17 cells. Before seeding for the assay, cells were grown overnight in T cell medium supplemented with human serum (1%) overnight. The medium was removed and replaced with unsupplemented RPMI for 4 hours before the assay.

[0292] To measure IL-17F levels, 200,000 cells were seeded in 96-well plates and pre-incubated with compounds for 30 min, followed by stimulation with 6.25 ng / ml recombinant IL-23 and 0.1 ng / ml recombinant human IL-1B for 48 h. Supernatants were removed and IL-17F levels were measured using a commercially available ELISA kit (Thermo Fisher; BMS2037-2).

[0293] To measure pSTAT3 levels, 200,000 cells were seeded in a 96-well plate, pre-incubated with compounds for 30 min, followed by stimulation with 12.5 ng / ml recombinant IL-23 for 15 min, and then lysed using cell lysis buffer. pSTAT3 levels in the lysates were measured using a commercially available ELISA kit (Thermo Fisher; 85-86102-11).

[0294] ELISA was performed according to the manufacturer's instructions and absorbance was read using a microplate reader (Thermo Fisher; Varioskan). Data was normalized to the response in untreated samples using the following formula: % of control = ((stimulated sample concentration - unstimulated sample concentration) x 100) / (stimulated control concentration - unstimulated control concentration)

[0295] ICs were calculated using a nonlinear four-parameter logistic regression model (4PL) using Graphpad Prism 8.1.0. 50 values ​​were calculated.

[0296] The results are shown in Tables 19A and 19B below: [Table 33] [Table 34]

[0297] All tested compounds demonstrated inhibition of IL17-F production and STAT3 phosphorylation, however compound (1) was shown to be more active than comparative compound B in both assays.

[0298] Comparative Data – Conclusion The data obtained from assays (i)-(vi) above demonstrate that the compound of formula (1) has significant advantages over the most structurally similar compound (compound B) in WO 2015 / 032423.

[0299] Thus, compound (1) is more active than compound B in TYK2 kinase inhibition assays and has greater selectivity for TYK2 over JAK1, JAK2 and JAK3 kinases than compound B.

[0300] Compound (1) has slightly more advantageous properties than the prior art comparative compound B in cytochrome P450 assays, particularly in the CYP2C8 and CYP2C9 assays.

[0301] Compound (1) has a reduced hERG risk compared to the comparative compound B of the prior art.

[0302] Compound (1) exhibited a reduced clearance rate and consequently a longer half-life than comparative compound B in a hepatocyte stability assay.

[0303] Furthermore, compound (1) is more potent than comparative compound B in inhibiting STAT3 phosphorylation in IL-22 stimulated HT29 and Th17 cells.

[0304] Finally, compound (1) exhibits greater inhibition of IL-17F production in Th17 cells compared to comparative compound B.

[0305] Taken together, the data indicate that compound (1) is a highly potent and selective TYK2 kinase inhibitor with excellent pharmacokinetic properties.

[0306] Example 7 Pharmaceutical preparations (i) Tablet formulation A tablet composition containing the crystalline form of the compound of formula (1) defined herein is prepared by mixing 50 mg of the compound with 197 mg of lactose (BP) as a diluent and 3 mg of magnesium stearate as a lubricant and compressing to form tablets in a known manner.

[0307] (ii) Capsule formulation A capsule formulation is prepared by mixing 100 mg of the crystalline form of the compound of formula (1) as defined herein with 100 mg of lactose and filling the resulting mixture into a standard opaque hard gelatin capsule.

[0308] (iii) Subcutaneous injection preparation A composition for subcutaneous administration is prepared by mixing the crystalline form of the compound of formula (1) as defined herein with pharmaceutical grade corn oil to a concentration of 5 mg / mL. The composition is sterilized and filled into a suitable container. The present disclosure includes the following preferred embodiments. [ 1] Formula (1):

change

change

[0023] A process for preparing a substantially crystalline form (Form A) of compound (1) as defined in any one of claims 2 to 5, comprising: (i) dispersing an amorphous form of compound (1) in an aqueous solvent selected from water, water / acetonitrile (e.g., 4:1 MeCN / water), and water / THF (e.g., 4:1 THF / water) to form a mixture; (ii) heating the mixture to a moderately elevated temperature in the range of 45-65° C. and holding the mixture at the moderately elevated temperature for at least 10 hours (e.g., 10-25 hours, e.g., about 17 hours); (iii) cooling or allowing the mixture to cool from the moderately elevated temperature to a lower temperature in the range of 15-30° C. (e.g., 20-30° C., e.g., about 25° C.) and holding the mixture at the lower temperature for at least 2 hours (e.g., 2-8 hours, e.g., about 4.5 hours); and (iv) heating the mixture to a moderately elevated temperature in the range of 45-65° C. and holding the mixture at the moderately elevated temperature for at least 10 hours (e.g., 10-25 hours, e.g., about 16 hours); optionally subjecting the mixture to further heating and cooling cycles, including cooling the mixture to a lower temperature in the range of 15-30° C. (e.g., 20-30° C., e.g., about 25° C.) and optionally holding the mixture at the lower temperature for at least 30 minutes (e.g., up to about 1 hour); and (v) isolating (e.g., by filtration) the crystalline form A of compound (1) thus formed. [7] Formula (1):

change

[10] A substantially crystalline form of the compound of formula (1) according to [9] (Form B), having an X-ray powder diffraction pattern characterised by the presence of major peaks at diffraction angles (2θ) of 23.2° and / or 16.7° and / or 22.6° and / or 26.6° and / or 12.0° (e.g. at least four, more particularly at least five diffraction angles), and optionally one or more additional peaks at diffraction angles (2θ) selected from 23.4°, 25.3°, 7.1°, 19.9° and 27.8° (±0.2°).

[11]

[0023] A process for preparing a substantially crystalline form (form B) of compound (1) as defined in any one of claims 7 to 10, comprising: (i) Hydrocarbon solvents, halogenated hydrocarbon solvents (other than dichloromethane), methanol, isopropyl alcohol, aliphatic ketones (e.g., C 1-8 ketones), non-aromatic ethers (e.g., C3-6 dispersing an amorphous form of compound (1) in a solvent selected from dialkyl and alkyl cycloalkyl ethers and THF, and isopropyl acetate to form a mixture; (ii) heating the mixture to a moderately elevated temperature in the range of 45-65° C. and holding the mixture at the moderately elevated temperature for at least 10 hours (e.g., 10-25 hours, e.g., about 17 hours); (iii) cooling or allowing the mixture to cool from the moderately elevated temperature to a lower temperature in the range of 15-30° C. (e.g., 20-30° C., e.g., about 25° C.) and holding the mixture at the lower temperature for at least 2 hours (e.g., 2-8 hours, e.g., about 4.5 hours); and (iv) heating the mixture to a moderately elevated temperature in the range of 45-65° C. and holding the mixture at the moderately elevated temperature for at least 10 hours (e.g., 10-25 hours, e.g., about 16 hours); optionally subjecting the mixture to further heating and cooling cycles, including cooling the mixture to a lower temperature in the range of 15-30° C. (e.g., 20-30° C., e.g., about 25° C.) and optionally holding the mixture at the lower temperature for at least 30 minutes (e.g., up to about 1 hour); and (v) isolating (e.g., by filtration) the crystalline form B of compound (1) thus formed.

[12]

[0023] A process for preparing a substantially crystalline form (form B) of compound (1) as defined in any one of claims 7 to 10, comprising: (i) dispersing a solid form of compound (1) in methyl ethyl ketone (MEK) to form a mixture; (ii) subjecting the mixture to an equilibration procedure comprising periods of heating and cooling the mixture until a suspension of crystalline form B is formed; and optionally, further equilibrating the mixture until a desired level of polymorphic purity is achieved.

[13] Formula (1): [ka] wherein the crystalline form is Form C as defined herein.

[14] A substantially crystalline form of the compound of formula (1) according to

[13] (Form C), having an X-ray powder diffraction pattern characterised by the presence of major peaks at diffraction angles (2θ) of 12.8° and / or 17.8° and / or 22.9° and / or 24.3° and / or 8.5°.

[15] A substantially crystalline form of the compound of formula (1) according to

[14] (Form C), having an X-ray powder diffraction pattern characterised by the presence of major peaks at diffraction angles (2θ) of 12.8° and / or 17.8° and / or 22.9° and / or 24.3° and / or 8.5° (e.g. at least four, more particularly at least five diffraction angles), and optionally one or more additional peaks at diffraction angles (2θ) selected from 13.0°, 20.1°, 16.5°, 26.1° and 22.4° (±0.2°).

[16] Formula (1): [ka] wherein the crystalline form is Form D as defined herein.

[17]

[0023] A pharmaceutical composition comprising a crystalline form of a compound having formula (1) as defined in any one of items 1-5, 7-10 and 13-16, and a pharma- ceutically acceptable excipient.

[18] An invention as defined in any one of embodiments 1.0 to 1.20, 2.1 to 2.21, 3.1 to 3.15, 4.1 to 4.15, 5.1, 5.2, 6.1 to 6.15, 7.1 to 7.12, and 8.1 to 8.3.

[0309] Equivalent The foregoing examples are presented for the purpose of illustrating the present invention and should not be construed as imposing any limitations on the scope of the present invention. It will be readily apparent that numerous modifications and variations may be made to the specific embodiments of the present invention described above and illustrated in the examples without departing from the principles underlying the invention. All such modifications and variations are intended to be encompassed by this application.

Claims

1. Formula (1): 【Chemistry 1】 A crystal of a compound having a crystal purity of at least 90%; A crystal of the compound having a powder X-ray diffraction pattern (measured using Cu Kα radiation) characterized by the presence of major peaks at diffraction angles (2θ) of 23.2°, 16.7°, 22.6°, 26.6° and 12.0° (±0.2°).

2. A crystal of the compound of formula (1) described in claim 1, having a powder X-ray diffraction pattern (measured using Cu Kα radiation) further characterized by the presence of one or more additional peaks at diffraction angles (2θ) selected from the group consisting of 23.4°, 25.3°, 7.1°, 19.9° and 27.8° (±0.2°).

3. A crystal of the compound of formula (1) described in claim 2, having a powder X-ray diffraction pattern (measured using Cu Kα radiation) characterized by the presence of one or more additional peaks at diffraction angles (2θ) selected from the group consisting of 14.2°, 27.0°, 24.1°, 28.9° and 14.5° (±0.2°).

4. A process for preparing a crystal of a compound of formula (1) as defined in any one of claims 1 to 3, comprising: (i) dispersing an amorphous form of the compound of formula (1) in a solvent selected from the group consisting of a hydrocarbon solvent, a halogenated hydrocarbon solvent (other than dichloromethane), methanol, isopropyl alcohol, an aliphatic ketone, a non-aromatic ether, and isopropyl acetate to form a mixture; (ii) heating the mixture to a moderately elevated temperature in the range of 45-65° C. and holding the mixture at the moderately elevated temperature for at least 10 hours; (iii) cooling or allowing the mixture to cool from the moderately elevated temperature to a lower temperature in the range of 15-30° C. and holding the mixture at the lower temperature for at least 2 hours; and (iv) optionally subjecting the mixture to further heating and cooling cycles, including heating the mixture to a moderately elevated temperature in the range of 45-65° C. and holding the mixture at the moderately elevated temperature for at least 10 hours; cooling the mixture to a lower temperature in the range of 15-30° C. and optionally holding the mixture at the lower temperature for at least 30 minutes; and (v) isolating the crystals of the compound of formula (1) thus formed.

5. A process for preparing a crystal of a compound of formula (1) as defined in any one of claims 1 to 3, comprising: (i) dispersing a solid form of a compound of formula (1) in methyl ethyl ketone (MEK) to form a mixture; (ii) subjecting the mixture to an equilibration procedure comprising periods of heating and cooling the mixture until a suspension of crystals of the compound of formula (1) is formed; and optionally, further equilibrating the mixture until a desired level of polymorphic purity is achieved.

6. Formula (1): 【Chemistry 2】 A crystal of a compound having the formula: wherein the crystal has a crystalline purity of at least 90% and has a powder X-ray diffraction pattern (measured using Cu Kα radiation) characterized by the presence of major peaks at diffraction angles (2θ) of 23.1°, 12.3°, 16.7°, 20.7° and 13.7° (±0.2°).

7. A crystal of the compound of formula (1) according to claim 6, having a powder X-ray diffraction pattern (measured using Cu Kα radiation) characterized by the presence of one or more additional peaks at diffraction angles (2θ) selected from the group consisting of 21.9°, 20.8°, 10.7°, 23.6° and 21.4° (±0.2°).

8. A process for preparing a crystal of a compound of formula (1) as defined in claim 6 or 7, comprising: (i) dispersing an amorphous form of the compound of formula (1) in an aqueous solvent selected from the group consisting of water, water / acetonitrile and water / THF to form a mixture; (ii) heating the mixture to a moderately elevated temperature in the range of 45-65° C. and holding the mixture at the moderately elevated temperature for at least 10 hours; (iii) cooling or allowing the mixture to cool from the moderately elevated temperature to a lower temperature in the range of 15-30° C. and holding the mixture at the lower temperature for at least 2 hours; and (iv) heating the mixture to a moderately elevated temperature in the range of 45-65° C. and holding the mixture at the moderately elevated temperature for at least 10 hours; optionally subjecting the mixture to further heating and cooling cycles, including cooling the mixture to a lower temperature in the range of 15-30° C. and optionally holding the mixture at the lower temperature for at least 30 minutes; and (v) isolating the crystals of the compound of formula (1) thus formed.

9. Formula (1): 【Chemistry 3】 A crystal of a compound having the formula: wherein the crystal has a crystalline purity of at least 90% and has a powder X-ray diffraction pattern (measured using Cu Kα radiation) characterized by the presence of major peaks at diffraction angles (2θ) of 12.8°, 17.8°, 22.9°, 24.3° and 8.5° (±0.2°).

10. A crystal of the compound of formula (1) according to claim 9, having a powder X-ray diffraction pattern (measured using Cu Kα radiation) characterized by the presence of one or more additional peaks at diffraction angles (2θ) selected from the group consisting of 13.0°, 20.1°, 16.5°, 26.1° and 22.4° (±0.2°).

11. A crystal of a compound having the formula (1) according to any one of claims 1 to 3, 6 to 7 and 9 to 10, having a crystal purity of at least 95%.

12. A pharmaceutical composition comprising a crystal of a compound having formula (1) as defined in any one of claims 1 to 3, 6 to 7 and 9 to 11, and a pharma- ceutically acceptable excipient.

13. A crystal of a compound having formula (1) as defined in any one of claims 1 to 3, 6 to 7 and 9 to 11, a) a disease or condition in which TYK2 kinase is involved; b) an inflammatory or immunological disease; or c) autoimmune disease A pharmaceutical composition for the treatment of

Images